

# Appendix 1

## **Core Outcome Measurement Set for Research and Clinical Practice in Post COVID-19 Condition (Long COVID) in Children and Young People: An International Delphi Consensus Study ‘PC-COS Children’**

Nina Seylanova MD\*<sup>1</sup>, Anastasia Chernyavskaya MD\*<sup>2,3</sup>, Natalia Degtyareva BSc<sup>4</sup>, Aigun Mursalova MD<sup>4</sup>, Ali Ajam BSc<sup>4</sup>, Lin Xiao BSc<sup>4</sup>, Khazhar Aktulaeva BSc<sup>4</sup>, Philipp Roshchin BSc<sup>4</sup>, Polina Bobkova MD<sup>4</sup>, Olalekan Lee Aiyegbusi PhD<sup>5</sup>, Anbarasu Theodore Anbu MD<sup>6</sup>, Christian Apfelbacher PhD<sup>7</sup>, Ali Akbar Asadi-Pooya MD<sup>8,9</sup>, Liat Ashkenazi-Hoffnung MD<sup>10</sup>, Caroline Brackel MD<sup>11,12</sup>, Danilo Buonsenso MD, PhD<sup>13,14</sup>, Wouter de Groote<sup>15</sup>, Janet V. Diaz MD<sup>15</sup>, Daniele Dona MD, PhD<sup>16</sup>, Audrey Dunn Galvin PhD<sup>17</sup>, Jon Genuneit<sup>18</sup>, Helen Goss<sup>19</sup>, Sarah E. Hughes PhD<sup>20</sup>, Christina J Jones PhD<sup>21</sup>, Krutika Kuppalli MD<sup>15</sup>, Laura A. Malone MD, PhD<sup>22,23</sup>, Sammie McFarland<sup>19</sup>, Dale M. Needham, MD, PhD<sup>24,25,26</sup>, Nikita Nekliudov MD, MSc<sup>27</sup>, Timothy R Nicholson PhD<sup>28</sup>, Carlos R. Oliveira MD, PhD<sup>29,30,31</sup>, Nicoline Schiess<sup>32</sup>, Terry Y Segal MD<sup>33</sup>, Louise Sigfrid<sup>34</sup>, Claire Thorne PhD<sup>35</sup>, Susanne Vijverberg PhD<sup>36</sup>, John O. Warner<sup>37</sup>, Wilson Milton Were<sup>15</sup>, Paula R. Williamson PhD<sup>38</sup>, Daniel Munblit MD, PhD\*<sup>39,40,41</sup>, and the PC-COS Children Study Group\*\*

1 Independent researcher, London, UK

2 Department of Paediatrics and Paediatric Rheumatology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

3 National Medical Research Center for Children's Health, Moscow, Russia

4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

5 University of Birmingham, Birmingham, UK

6 Alder Hey Children's NHS Foundation Trust, Liverpool, UK

7 University of Magdeburg, Magdeburg, Germany

8 Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

9 Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USA

10 Schneider Children's Medical Center of Israel, Petah Tikva, Israel

11 Amsterdam University Medical Centers, Amsterdam, the Netherlands

- 12 Department of Pediatrics, Tergooi Hospital, Blaricum, the Netherlands
- 13 Università Cattolica del Sacro Cuore, Rome, Italy
- 14 Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 15 World Health Organization, Switzerland
- 16 Department for Women's and Children's Health, University of Padua, Padua, Italy
- 17 University of Cork, Cork, Ireland
- 18 Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany
- 19 Long Covid Kids Charity, UK
- 20 Institute of Applied Health Research, University of Birmingham, Birmingham, UK
- 21 University of Surrey, Guildford, UK
- 22 Kennedy Krieger Institute, Baltimore, USA
- 23 Johns Hopkins University, Baltimore, USA
- 24 Outcomes After Critical Illness and Surgery (OACIS) Research Group, Johns Hopkins University, Baltimore, USA
- 25 Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
- 26 Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, USA
- 27 Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
- 28 King's College London, London, UK
- 29 Yale University School of Medicine, Department of Pediatrics, Section of Infectious Diseases, New Haven, USA
- 30 Yale University School of Public Health, Department of Biostatistics, Division of Health Informatics, New Haven, USA
- 31 Yale New Haven Children's Hospital, New Haven, USA
- 32 Brain Health Unit, Mental Health and Substance Use Department, World Health Organization, Switzerland

33 University College London Hospitals NHS Foundation Trust, London, UK

34 ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK

35 Population, Policy and Practice Research and Teaching Dept, University College London GOS Institute of Child Health, London, UK

36 Amsterdam University Medical Centers, Amsterdam, the Netherlands

37 Imperial College London, London, UK

38 Department of Health Data Science, University of Liverpool, Liverpool, UK

39 Division of Care in Long Term Conditions, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK

40 Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

41 Research and Clinical Center for Neuropsychiatry, Moscow, Russia

\*Authors contributed equally to the study: apart from the two joint first authors, who contributed equally, the primary study team members and the last author, authors are listed in alphabetical order.

\*\* Listed at end of the manuscript

**Corresponding author:**

Daniel Munblit MD, PhD. Division of Care in Long Term Conditions, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, United Kingdom

Email: [daniel.munblit@kcl.ac.uk](mailto:daniel.munblit@kcl.ac.uk)

## **Table of Contents**

<b>1. SYSTEMATIC REVIEW SEARCH STRATEGY</b>	<b>4</b>
<b>2. REFERENCES USED FOR THE DEVELOPMENT OF THE LONG LIST OF OUTCOMES.</b>	<b>10</b>
<b>3. THE LONG LIST OF OUTCOMES USED IN POST-COVID-19 CONDITION STUDIES.</b>	<b>27</b>
<b>4. THE LIST OF OUTCOMES PRESENTED TO THE DELPHI PARTICIPANTS.</b>	<b>80</b>
<b>5. FULL DETAILS OF DELPHI PARTICIPANTS.</b>	<b>83</b>
<b>6. ATTRITION BETWEEN ROUNDS ONE AND TWO.</b>	<b>89</b>
<b>7. RESULTS FOLLOWING TWO ROUNDS OF DELPHI AND SELECTION OF OUTCOMES FOR THE CONSENSUS MEETING</b>	<b>90</b>
<b>8. DELPHI PROCESS AND CONSENSUS MEETING RESULTS</b>	<b>95</b>
<b>9. PC-COS CHILDREN PROJECT STEERING COMMITTEE GROUP AUTHORS</b>	<b>106</b>
<b>10. PC-COS CHILDREN PROJECT STEERING COMMITTEE (TABLE)</b>	<b>108</b>

## 1. Systematic review search strategy

The COS consensus process was informed by a comprehensive search of Medline, Embase, and the WHO COVID-19 Research Database. The search was limited to English-language publications and protocols. Data from research protocols were extracted from two clinical trials registries, Clinical Trials.gov and the International Clinical Trials Registry Platform.

### 1.1 Medline search strategy

Database: Ovid MEDLINE(R) ALL

Search Strategy:

- 1 exp child/
- 2 exp infant/
- 3 exp adolescent/
- 4 exp pediatrics/
- 5 "toddler\*".ab,ti.
- 6 "paediatric\*".ab,ti.
- 7 "pediatric\*".ab,ti.
- 8 baby.ab,ti.
- 9 babies.ab,ti.
- 10 "neonate\*".ab,ti.
- 11 "newborn\*".ab,ti.
- 12 "new born\*".ab,ti.
- 13 "girl\*".ab,ti.

- 14 "boy\*".ab,ti.
- 15 (kindergarten\* or preschool\* or school\*).ab,ti.
- 16 "teen\*".ab,ti.
- 17 "youth\*".ab,ti.
- 18 "juvenile\*".ab,ti.
- 19 (young adj (person or people)).ab,ti.
- 20 "minors\*".ab,ti.
- 21 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
- 22 (chronic adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 23 (persist\* adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 24 (sustain\* adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 25 (history adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 26 ((postcovid\* or post covid\* or postcoronavirus\* or postcorona\* virus\* or post coronavirus\* or post corona\* virus\* or postcoronavirus\* or postcorono\* virus\* or post coronavirus\* or post corono\* virus\* or postcoronavirinae\* or postcorona\* virinae\* or post coronavirinae\* or post corona\* virinae\* or postCov or post Cov or postsars\* or post sars\* or "post severe acute respiratory syndrome\*" or postncov\* or post ncov\* or posthcov\* or post hcov\*) adj3 (syndrome\* or disorder\* or illness\* or sickness\* or disease\* or condition\* or symptom\* or sign\* or prognos\* or followup\* or "follow up\*" or feature\* or comorbid\* or "co morbid\*" or multimorbid\* or "multi morbid\*" or survivor\* or survival\* or risk\* or care\* or convalescen\* or recuperat\* or aftercare\* or ambulatory\* or outpatient\* or "out patient\*")).ab,ti.
- 27 ("long sars\*" or "post acute COVID\*" or "Covid\* syndrome" or "post-acute sequelae SARS-CoV-2 infection").ab,ti.
- 28 ((longhaul\* or long haul\* or long-haul\*) adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 29 ((long term or long-term or longterm) adj3 effect\* adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 30 (sequela\* adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.

- 31 (persistent symptoms or persistant symptoms or persisting symptoms or longlasting symptoms or long lasting symptoms or long term symptoms or long-term symptoms or longterm symptoms).mp. and (Betacoronavirus\* or Corona Virus\* or Coronavirus\* or Coronovirus\* or CoV or CoV2 or COVID or COVID19 or COVID-19 or HCoV-19 or nCoV or SARS CoV 2 or SARS2 or SARSCoV or SARS-CoV or SARS-CoV-2 or 2019nCoV).ab,ti.
- 32 (long\* adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 33 ((post acute or post-acute or postacute) adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 34 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
- 35 21 and 34

## 1.2 Embase search strategy

Database: Embase Classic+Embase

Search Strategy:

- 1 exp child/
- 2 exp infant/
- 3 exp adolescent/
- 4 exp pediatrics/
- 5 "toddler\*".ab,ti.
- 6 "paediatric\*".ab,ti.
- 7 "pediatric\*".ab,ti.
- 8 baby.ab,ti.
- 9 babies.ab,ti.
- 10 "neonate\*".ab,ti.

- 11 "newborn\*".ab,ti.
- 12 "new born\*".ab,ti.
- 13 "girl\*".ab,ti.
- 14 "boy\*".ab,ti.
- 15 (kindergarten\* or preschool\* or school\*).ab,ti.
- 16 "teen\*".ab,ti.
- 17 "youth\*".ab,ti.
- 18 "juvenile\*".ab,ti.
- 19 (young adj (person or people)).ab,ti.
- 20 "minors\*".ab,ti.
- 21 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
- 22 (chronic adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 23 (persist\* adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 24 (sustain\* adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 25 (history adj3 (covid\* or corona or coronavirus\*)).ab,ti.
- 26 ((postcovid\* or post covid\* or postcoronavirus\* or postcorona\* virus\* or post coronavirus\* or post corona\* virus\* or postcoronavirus\* or postcorono\* virus\* or post coronovirus\* or post corono\* virus\* or postcoronavirinae\* or postcorona\* virinae\* or post coronavirinae\* or post corona\* virinae\* or postCov or post Cov or postsars\* or post sars\* or "post severe acute respiratory syndrome\*" or postncov\* or post ncov\* or posthcov\* or post hcov\*) adj3 (syndrome\* or disorder\* or illness\* or sickness\* or disease\* or condition\* or symptom\* or sign\* or prognos\* or followup\* or "follow up\*" or feature\* or comorbid\* or "co morbid\*" or multimorbid\* or "multi morbid\*" or survivor\* or survival\* or risk\* or care\* or convalescen\* or recuperat\* or aftercare\* or ambulatory\* or outpatient\* or "out patient\*")).ab,ti.
- 27 ("long sars\*" or "post acute COVID\*" or "Covid\* syndrome" or "post-acute sequelae SARS-CoV-2 infection").ab,ti.
- 28 ((longhaul\* or long haul\* or long-haul\*) adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.



- 29 ((long term or long-term or longterm) adj3 effect\* adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 30 (sequela\* adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 31 (persistent symptoms or persistant symptoms or persisting symptoms or longlasting symptoms or long lasting symptoms or long term symptoms or long-term symptoms or longterm symptoms).mp. and (Betacoronavirus\* or Corona Virus\* or Coronavirus\* or Coronavirus\* or CoV or CoV2 or COVID or COVID19 or COVID-19 or HCoV-19 or nCoV or SARS CoV 2 or SARS2 or SARSCoV or SARS-CoV or SARS-CoV-2 or 2019nCoV).ab,ti.
- 32 (long\* adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 33 ((post acute or post-acute or postacute) adj3 (covid\* or ncov\* or novel coronavirus or novel betacoronavirus or sars-ncov-2 or sars-cov-2)).ab,ti.
- 34 exp long COVID/
- 35 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
- 36 21 and 35

### 1.3 The WHO COVID-19 Research Database search strategy

(tw:("long covid"~3 OR "long-covid" OR "long covid" OR "post-covid"~3 OR "post covid" OR "post-covid" OR "long term" OR "post acute" OR "post-acute" OR "chronic covid"~3 OR "post discharge" OR postdischarge\* OR "post-discharge" OR "after hospital" OR "persistent symptom" OR "persistent symptoms" OR "after hospitalisation" OR "after hospitalization" OR "after sars" OR "after covid" OR "long haul" OR "persistant effects" OR "persistent effects" OR "prolonged symptoms" OR "prolonged symptom" )) AND (tw:(mh:("Child" OR "Maternal-Child Health Centers" OR "Child Nutrition Sciences" OR "Child Health Services" OR "Child Nutritional Physiological Phenomena" OR "Child Nutrition Disorders" OR "Child Mortality" OR "Child Welfare" OR "Child Care" OR "Child Reactive Disorders" OR "Child Guidance" OR "Child Reactive Disorders" OR "Child Behavior Disorders" OR "Child, Orphaned" OR "Child, Institutionalized" OR "Child, Hospitalized" OR "Child Development" OR "Child Behavior" OR "Developmental Disabilities" OR "Mental Disorders Diagnosed in Childhood" OR "Disabled Children" OR "Pediatric Nursing"OR "Pediatric Nursing" OR "Pediatric Assistants" OR "Hospitals, Pediatric" OR "Intensive Care Units, Pediatric" OR "Pediatrics" OR "Pediatricians") OR child OR children OR newborn\* OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile OR "young patient" OR "young patients" OR "young people" OR "paediatricians" OR "Pediatrician" OR "paediatrician" OR "Pediatrics" OR "paediatrics" OR Pediatric OR paediatric ))

## 2. References used for the development of the long list of outcomes.

1. References from initial systematic review	
1a. Original studies	
Document type	Study title
1	Preprint Dumont R, Nehme M, Lorthe E, et al. Persistent symptoms among children and adolescents with and without anti-SARS-CoV-2 antibodies: a population-based serological study in Geneva, Switzerland. medRxiv. Published online January 1, 2021:2021.12.23.21268298. doi:10.1101/2021.12.23.21268298
2	Preprint Miller F, Nguyen V, Navaratnam AMD, et al. Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. medRxiv. Published online January 1, 2021:2021.05.28.21257602. doi:10.1101/2021.05.28.21257602
3	Preprint Roessler M, Tesch F, Batram M, et al. Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19. medRxiv. Published online January 1, 2021:2021.10.21.21265133. doi:10.1101/2021.10.21.21265133
4	Preprint Knoke L, Schlegtendal A, Maier C, Eitner L, Lücke T, Brinkmann F. More complaints than findings - Long-term pulmonary function in children and adolescents after COVID-19. medRxiv. Published online January 1, 2021:2021.06.22.21259273. doi:10.1101/2021.06.22.21259273
5	Preprint Sante G Di, Buonsenso D, Rose C De, et al. Immune profile of children with post-acute sequelae of SARS-CoV-2 infection (Long Covid). medRxiv. Published online 2021. doi: 10.1101/2021.05.07.21256539
6	Preprint Larsen VB, Størdal K, Telle K, Methi F, Magnusson K. A comparison of health care use after severe COVID-19, respiratory syncytial virus, and influenza in children. medRxiv. Published online January 1, 2021:2021.11.22.21266522. doi:10.1101/2021.11.22.21266522
7	Preprint Heiss R, Wagner A, Tan L, et al. Persisting pulmonary dysfunction in pediatric post-acute Covid-19. medRxiv. Published online January 1, 2022:2022.02.21.22270909. doi:10.1101/2022.02.21.22270909
8	Article Asadi-Pooya AA, Nemati H, Shahisavandi M, et al. Long COVID in children and adolescents [published correction

		appears in World J Pediatr. 2022 Jul 3;:]. World J Pediatr. 2021;17(5):495-499. doi:10.1007/s12519-021-00457-6
<b>9</b>	Article	Zavala M, Ireland G, Amin-Chowdhury Z, Ramsay ME, Ladhani SN. Acute and Persistent Symptoms in Children With Polymerase Chain Reaction (PCR)-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Compared With Test-Negative Children in England: Active, Prospective, National Surveillance. Clin Infect Dis. 2022;75(1):e191-e200. doi:10.1093/cid/ciab991
<b>10</b>	Article	Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S, et al. Long COVID in Children: Observations From a Designated Pediatric Clinic. Pediatr Infect Dis J. 2021;40(12):e509-e511. doi:10.1097/INF.0000000000003285
<b>11</b>	Article	María Bergia, Elena Sanchez-Marcos, Blanca Gonzalez-Haba et al. Study of Prevalence and Characteristics of Long Covid in Spanish Children, 14 December 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-1068678/v1]
<b>12</b>	Article	Cara J Bossley, Ema Kavaliunaite, Katharine Harman et al. Post-Acute COVID-19 Outcomes In Children Requiring Hospitalisation, 12 November 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-1001103/v1]
<b>13</b>	Article	Brackel CLH, Lap CR, Buddingh EP, et al. Pediatric long-COVID: An overlooked phenomenon?. Pediatr Pulmonol. 2021;56(8):2495-2502. doi:10.1002/ppul.25521
<b>14</b>	Article	Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110(7):2208-2211. doi:10.1111/apa.15870
<b>15</b>	Article	Roge I, Smane L, Kivite-Urtane A, et al. Comparison of Persistent Symptoms After COVID-19 and Other Non-SARS-CoV-2 Infections in Children. Front Pediatr. 2021;9:752385. Published 2021 Oct 29. doi:10.3389/fped.2021.752385
<b>16</b>	Article	Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents [published online ahead of print, 2021 Jul 15]. JAMA. 2021;326(9):869-871. doi:10.1001/jama.2021.11880
<b>17</b>	Article	Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J. 2022;59(2):2101341. Published 2022 Feb 3. doi:10.1183/13993003.01341-2021
<b>18</b>	Article	Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2 [published correction appears in Lancet Child Adolesc Health. 2021 Aug 31;:]. Lancet Child Adolesc Health. 2021;5(10):708-718. doi:10.1016/S2352-4642(21)00198-X

<b>19</b>	Article	Erol N, Alpinar A, Erol C, Sari E, Alkan K. Intriguing new faces of Covid-19: persisting clinical symptoms and cardiac effects in children. <i>Cardiol Young</i> . 2022;32(7):1085-1091. doi:10.1017/S1047951121003693
<b>20</b>	Article	Fink TT, Marques HHS, Gualano B, et al. Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital [published correction appears in <i>Clinics (Sao Paulo)</i> . 2022 Mar 3;77:100024]. <i>Clinics (Sao Paulo)</i> . 2021;76:e3511. Published 2021 Nov 26. doi:10.6061/clinics/2021/e3511
<b>21</b>	Article	Lars Christian Lund, Jesper Hallas, Henrik Nielsen et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. <i>Lancet Infect Dis</i> 2021; 21: 1373–82. Published Online May 10, 2021. doi: 10.1016/S1473-3099(21)00211-5
<b>22</b>	Article	Leftin Dobkin SC, Collaco JM, McGrath-Morrow SA. Protracted respiratory findings in children post-SARS-CoV-2 infection. <i>Pediatr Pulmonol</i> . 2021;56(12):3682-3687. doi:10.1002/ppul.25671
<b>23</b>	Article	Guemes-Villahoz N, Burgos-Blasco B, Perez-Garcia P, et al. Retinal and peripapillary vessel density increase in recovered COVID-19 children by optical coherence tomography angiography. <i>J AAPOS</i> . 2021;25(6):325.e1-325.e6. doi:10.1016/j.jaapos.2021.06.004
<b>24</b>	Article	Clavenna A, Francesco CD, Maio LD, et al. Risk of Sequelae of COVID-19 in Children Cared for by Primary Care Pediatricians. <i>Indian Pediatr</i> . 2022;59(1):87-88. doi:10.1007/s13312-022-2427-3
<b>25</b>	Article	Matteudi T, Luciani L, Fabre A, et al. Clinical characteristics of paediatric COVID-19 patients followed for up to 13 months. <i>Acta Paediatr</i> . 2021;110(12):3331-3333. doi:10.1111/apa.16071
<b>26</b>	Article	Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. <i>Lancet Child Adolesc Health</i> . 2021;5(6):e22-e23. doi:10.1016/S2352-4642(21)00124-3
<b>27</b>	Article	Smane L, Stars I, Pucuka Z, Roge I, Pavare J. Persistent clinical features in paediatric patients after SARS-CoV-2 virological recovery: a retrospective population-based cohort study from a single centre in Latvia. <i>BMJ Paediatr Open</i> . 2020;4(1):e000905. Published 2020 Dec 29. doi:10.1136/bmjpo-2020-000905
<b>28</b>	Article	Zhang J, Xu J, Zhou S, et al. The characteristics of 527 discharged COVID-19 patients undergoing long-term follow-up in China. <i>Int J Infect Dis</i> . 2021;104:685-692. doi:10.1016/j.ijid.2021.01.064
<b>29</b>	Article	Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients. <i>Clin Infect Dis</i> . 2021;73(11):e4058-e4063. doi:10.1093/cid/ciaa1792
<b>30</b>	Article	Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. <i>Eur J Pediatr</i> . 2022;181(4):1597-1607. doi:10.1007/s00431-021-

		04345-z
31	Article	Stephenson T, Pinto Pereira SM, Shafran R, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLOcK): a national matched cohort study. <i>Lancet Child Adolesc Health</i> . 2022;6(4):230-239. doi:10.1016/S2352-4642(22)00022-0
32	Article	Karolina Dolezalova, Jana Tukova, Petr Pohunek. Respiratory Consequences of Pediatric Post-COVID Syndrome: Case Series. <i>Authorea</i> . October 28, 2021. DOI: 10.22541/au.163544403.31818690/v1
33	Article	Sterky E, Olsson-Åkefeldt S, Hertting O, et al. Persistent symptoms in Swedish children after hospitalisation due to COVID-19. <i>Acta Paediatr</i> . 2021;110(9):2578-2580. doi:10.1111/apa.15999
34	Article	Smame L, Roge I, Pucuka Z, Pavare J. Clinical features of pediatric post-acute COVID-19: a descriptive retrospective follow-up study. <i>Ital J Pediatr</i> . 2021;47(1):177. Published 2021 Aug 26. doi:10.1186/s13052-021-01127-z
35	Article	Khodeir MM, Shabana HA, Rasheed Z, et al. COVID-19: Post-recovery long-term symptoms among patients in Saudi Arabia. <i>PLoS One</i> . 2021;16(12):e0260259. Published 2021 Dec 8. doi:10.1371/journal.pone.0260259
36	Article	Denina M, Pruccoli G, Scolfaro C, et al. Sequelae of COVID-19 in Hospitalized Children: A 4-Months Follow-Up. <i>Pediatr Infect Dis J</i> . 2020;39(12):e458-e459. doi:10.1097/INF.0000000000002937
37	Article	Chapagain RH, Adhikari S, Pokharel S, Shrestha SM, Bichha RP. Presenting Clinico-laboratory Characteristics, Hospital Course and Outcomes of Admitted Children with COVID19 in a Tertiary Pediatric Hospital of Nepal. <i>J Nepal Health Res Counc</i> . 2021;19(2):349-354. Published 2021 Sep 6. doi:10.33314/jnhrc.v19i2.3569
38	Article	Smith MP. Estimating total morbidity burden of COVID-19: relative importance of death and disability. <i>J Clin Epidemiol</i> . 2022;142:54-59. doi:10.1016/j.jclinepi.2021.10.018
39	Article	Parisi GF, Diaferio L, Brindisi G, et al. Cross-Sectional Survey on Long Term Sequelae of Pediatric COVID-19 among Italian Pediatricians. <i>Children (Basel)</i> . 2021;8(9):769. Published 2021 Aug 31. doi:10.3390/children8090769
40	Article	Hernandez-Romieu AC, Carton TW, Saydah S, et al. Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2. <i>JAMA Netw Open</i> . 2022;5(2):e2147053. Published 2022 Feb 1. doi:10.1001/jamanetworkopen.2021.47053
<b>1b. Clinical trials protocols</b>		

	<b>Trial ID</b>	<b>Study title</b>
<b>1</b>	ChiCTR2000038134	Half-year follow-up of novel coronavirus pneumonia (COVID-19) rehabilitated patients in Chongqing Municipality
<b>2</b>	ChiCTR2000033980	A follow-up study of novel coronavirus pneumonia (COVID-19) patients in Wanzhou District, Chongqing
<b>3</b>	ChiCTR2100043802	Follow up study on health status of rehabilitation patients with novel coronavirus pneumonia (COVID-19)
<b>4</b>	CTRI/2020/11/029026	Assessment of long term respiratory sequelae in children who had infection with COVID 19 virus.
<b>5</b>	CTRI/2021/01/030235	Lung Function Indices Measured by Forced Oscillation Test in Post Covid patients: An Observational Study.
<b>6</b>	ISRCTN34804192	Study of children and young people who may be experiencing long COVID
<b>7</b>	NCT05172011	Understanding the Long-term Impact of COVID on Children and Families
<b>8</b>	CTRI/2020/07/026821	Study of dermatological changes post COVID-19 illness within 3 months of recovery.
<b>9</b>	NCT04479293	Post COVID-19 Functional Status in Egypt
<b>10</b>	NCT04799444	LATE-COVID/LATE-COVID-Kids - Observational Study in Children and Adults (LATE-COVID)
<b>11</b>	ACTRN12620000527965	Neonatal CoVID-19 Study to evaluate the population health impacts of COVID-19 in mothers and their newborn infants cared for in tertiary and non-tertiary hospitals in Australia.
<b>12</b>	NL8926	Clinical features of COVID-19 in Pediatric Patients, long term effects
<b>13</b>	ChiCTR2000032895	Epidemiological, clinical and prognosticated features of novel coronavirus pneumonia (COVID-19) in Zhuhai
<b>14</b>	ChiCTR2000030849	Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies
<b>15</b>	CTRI/2020/06/025588	Clinical profile and outcomes of patients with Corona virus disease 19 (COVID – 19) admitted to a tertiary care hospital in Mumbai.
<b>16</b>	DRKS00024835	"LONG-COVID-19" also in pediatric patients. A pilot study asking if a comprehensive aftercare is necessary for children and young adults after a SARS-CoV-2 infection
<b>17</b>	NCT04741412	Pediatric SARS-CoV-2 Infections: Course of COVID-19, Immune Responses, Complications and Long-term

	Consequences (PEDCOVID-19)
<b>18</b>	NCT05097677 Follow-up of Covid-19 Long Term Sequelae
<b>19</b>	NCT04335773 COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology
<b>20</b>	NCT04588363 COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM)
<b>21</b>	ChiCTR2100048440 Study on the correlation between multi-omics parameters and clinical features, severity and prognosis of COVID-19 patients
<b>22</b>	ChiCTR2000038943 Outcomes of and Prognosis Factors for COVID-19 Patients: an Observational Study
<b>23</b>	CTRI/2020/05/025221 Create registry of Childhood Cancer patients in India with COVID 19 to provide guidelines for prevention and treatment
<b>24</b>	CTRI/2020/11/029058 Cross sectional study to assess the impact of COVID 19 infection on pulmonary function tests in children
<b>25</b>	NCT04270383 Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
<b>26</b>	NCT04342702 A Study on the Prospective Cohort Library of COVID-19 in Southern
<b>27</b>	NCT04359914 Neurocognitive Impairment in Patients With COVID-19 (NCoV)
<b>28</b>	NCT04379089 Neurologic Manifestations of COVID 19 in Children
<b>29</b>	NCT04388436 Post Covid-19 Cardiopulmonary and Immunological Changes (covid-19)
<b>30</b>	NCT04448145 Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence (C-PIC)
<b>31</b>	NCT04448717 COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children (CiaoCorona)
<b>32</b>	NCT04449978 TARGeT Kids! COVID-19 Study of Children and Families
<b>33</b>	NCT04632719 The MentalPlus® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19 (MP-COVID)
<b>34</b>	NCT04659486 Adolescents With COVID-19/MIS-C at HCFMUSP

<b>35</b>	NCT04686734	Long-term Effects of COVID-19 in Adolescents (LoTECA)
<b>36</b>	NCT04786353	Long COVID Kids DK - Investigating Long-term Covid-19
<b>37</b>	NCT04830852	Pediatric COVID Outcomes Study (PECOS)
<b>38</b>	NCT05059080	A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study (MEADOWSPRING)
<b>39</b>	NCT05074953	Post-COVID-19 Monitoring in Routine Health Insurance Data (POINTED)
<b>40</b>	NCT04346212	Oropharyngeal Dysphagia in Patients With COVID-19
<b>41</b>	NCT04410107	Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19
<b>42</b>	NCT04457505	One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19
<b>43</b>	NCT04523051	Rehabilitation After Admission in Intensive Care Unit for COVID-19 (RECOVER)
<b>44</b>	NCT04702945	Canadian COVID-19 Emergency Department Registry (CCEDRRN)
<b>45</b>	NCT04724850	Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura (COVIXTREM)
<b>46</b>	NCT04764773	Persistence of Symptoms After Improvement of Acute COVID-19 (COVID-19)
<b>47</b>	NCT04846010	Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 (sequelae)
<b>48</b>	NCT04900961	CISCO-21 Prevent and Treat Long COVID-19. (CISCO-21)
<b>49</b>	NCT05004246	Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study
<b>50</b>	NCT05130736	Rehabilitation Robot in Patients With Post-Coronavirus Disease (COVID-19) Fatigue Syndrome
<b>1c. Additional</b>		
	<b>Document type</b>	<b>Title</b>
<b>1</b>	Case report form (CRF)	ISARIC COVID-19 & other acute respiratory infections Initial Follow Up Survey for children and young people (less than 18 years of age) v.1.3 (18 October 2021)



## 2. References from additional systematic review

### 2a. Original studies

	Document type	Study title
1	Preprint	Britton, P. N., Burrell, R., Chapman, E., Boyle, J., Alexander, S., Belessis, Y., Dalby-Payne, J., Knight, K., Lau, C., McMullan, B., Milne, B., Paull, M., Nguyen, J., Selvadurai, H., Dale, R., & Baillie, A. (2023). Post COVID-19 conditions in Children and Adolescents at 3 months following a Delta outbreak in Australia: a cohort study. MedRxiv, 2023.03.14.23287239. <a href="https://doi.org/10.1101/2023.03.14.23287239">doi.org/10.1101/2023.03.14.23287239</a>
2	Preprint	Sharanya, P., Mishra, D., Agarwal, A., & Keerthana, D. (2023). Pulmonary sequelae at six months in children with SARS-CoV-2 infection: <em>A Single-Centre Study</em>. MedRxiv, 2023.03.10.23286644. <a href="https://doi.org/10.1101/2023.03.10.23286644">doi.org/10.1101/2023.03.10.23286644</a>
3	Preprint	Zhang, Y., Romieu-Hernandez, A., Boehmer, T. K., Azziz-Baumgartner, E., Carton, T. W., Gundlapalli, A. v, Fearington, J., Nagavedu, K., Dea, K., Moyneur, E., Cowell, L. G., Kaushal, R., Mayer, K. H., Puro, J., Rasmussen, S. A., Thacker, D., Weiner, M. G., Saydeh, S., Block, J. P., & Partners, Pcor. N. (2022). Association between SARS-CoV-2 Infection and Select Symptoms and Conditions 31 to 150 Days After Testing among Children and Adults. MedRxiv, 2022.12.18.22283646. <a href="https://doi.org/10.1101/2022.12.18.22283646">https://doi.org/10.1101/2022.12.18.22283646</a>
4	Preprint	Dumont R, Richard V, Lorthe E, et al. A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents. Nat Commun. 2022;13(1):7086. Published 2022 Nov 29. doi:10.1038/s41467-022-34616-8
5	Preprint	Pajor, N. M., Lorman, V., Razzaghi, H., Case, A., Prahalad, P., Brill, S. B., Wu, Q., Chen, Y., Block, J., Patel, P. B., Rao, S., Mejias, A., Thacker, D., Jhaveri, R., Bailey, L. C., Forrest, C. B., & Lee, G. M. (2022). Healthcare utilization following SARS-CoV-2 infection in children and adolescents with chronic conditions: An EHR-based Cohort Study from the RECOVER Program. MedRxiv, 2022.07.08.22276768. <a href="https://doi.org/10.1101/2022.07.08.22276768">https://doi.org/10.1101/2022.07.08.22276768</a>
6	Preprint	Kendall, E. K., Olaker, V. R., Kaelber, D. C., Xu, R., & Davis, P. B. (2022). Elevated liver enzymes and bilirubin following SARS-CoV-2 infection in children under 10. MedRxiv, 2022.05.10.22274866. <a href="https://doi.org/10.1101/2022.05.10.22274866">doi.org/10.1101/2022.05.10.22274866</a>
7	Preprint	Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr. 2022;176(10):1000-1009. doi:10.1001/jamapediatrics.2022.2800
8	Preprint	Nugawela, M. D., Stephenson, T., Shafran, R., Stavola, B. L. de, Ladhani, S. N., Simmons, R., McOwatt, K., Rojas, N., Cheung, E. Y., Ford, T., Heyman, I., Crawley, E., & Pereira, S. M. P. (2022). Developing a model for predicting

		impairing physical symptoms in children 3 months after a SARS-CoV-2 PCR-test: The CLoCk Study. MedRxiv, 2022.04.01.22273117.doi.org/10.1101/2022.04.01.22273117
<b>9</b>	Preprint	Heiss R, Tan L, Schmidt S, et al. Pulmonary Dysfunction after Pediatric COVID-19. Radiology. 2023;306(3):e221250. doi:10.1148/radiol.221250
<b>10</b>	Article	Jarupan M, Jantarabenjakul W, Jaruampornpan P, et al. Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand. Vaccines (Basel). 2023;11(5):884. Published 2023 Apr 23. doi:10.3390/vaccines11050884
<b>11</b>	Article	Buonsenso D, Morello R, Mariani F, et al. Risk of long Covid in children infected with Omicron or pre-Omicron SARS-CoV-2 variants. Acta Paediatr. 2023;112(6):1284-1286. doi:10.1111/apa.16764
<b>12</b>	Article	Pinto Pereira SM, Mensah A, Nugawela MD, et al. Long COVID in Children and Young after Infection or Reinfection with the Omicron Variant: A Prospective Observational Study [published online ahead of print, 2023 May 11]. J Pediatr. 2023;259:113463. doi:10.1016/j.jpeds.2023.113463
<b>13</b>	Article	Buonsenso D, Morello R, Mariani F, De Rose C, Cortese R, Vetrugno L, Valentini P. Role of Lung Ultrasound in the Follow-Up of Children with Previous SARS-CoV-2 Infection: A Case-Control Assessment of Children with Long COVID or Fully Recovered. Journal of Clinical Medicine. 2023; 12(9):3342. https://doi.org/10.3390/jcm12093342
<b>14</b>	Article	Garai R, Krivácsy P, Herczeg V, et al. Clinical assessment of children with long COVID syndrome. Pediatr Res. 2023;93(6):1616-1625. doi:10.1038/s41390-022-02378-0
<b>15</b>	Article	Ertesvåg NU, Iversen A, Blomberg B, et al. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine. 2023;92:104599. doi:10.1016/j.ebiom.2023.104599
<b>16</b>	Article	Shachar-Lavie I, Shorer M, Segal H, Fennig S, Ashkenazi-Hoffnung L. Mental health among children with long COVID during the COVID-19 pandemic. Eur J Pediatr. 2023;182(4):1793-1801. doi:10.1007/s00431-023-04854-z
<b>17</b>	Article	Prato A, Salerno AM, Saia F, et al. Symptoms compatible with long COVID in an Italian pediatric cohort of Tourette patients with and without SARS-CoV-2 infection: a short-term follow-up assessment. BMC Pediatr. 2023;23(1):222. Published 2023 May 5. doi:10.1186/s12887-023-04035-9
<b>18</b>	Article	Angarita-Fonseca A, Torres-Castro R, Benavides-Cordoba V, et al. Exploring long COVID condition in Latin America: Its impact on patients' activities and associated healthcare use. Front Med (Lausanne). 2023;10:1168628. Published 2023 Apr 20. doi:10.3389/fmed.2023.1168628
<b>19</b>	Article	Ahn B, Choi SH, Yun KW. Non-neuropsychiatric Long COVID Symptoms in Children Visiting a Pediatric Infectious Disease Clinic After an Omicron Surge. Pediatr Infect Dis J. 2023;42(5):e143-e145.

		doi:10.1097/INF.0000000000003862
<b>20</b>	Article	Warren-Gash C, Lacey A, Cook S, et al. Post-COVID-19 condition and persisting symptoms in English schoolchildren: repeated surveys to March 2022. <i>BMC Infect Dis.</i> 2023;23(1):201. Published 2023 Apr 5. doi:10.1186/s12879-023-08203-1
<b>21</b>	Article	Miller F, Nguyen DV, Navaratnam AM, et al. Prevalence and Characteristics of Persistent Symptoms in Children During the COVID-19 Pandemic: Evidence From a Household Cohort Study in England and Wales [published correction appears in <i>Pediatr Infect Dis J.</i> 2023 May 1;42(5):438-439]. <i>Pediatr Infect Dis J.</i> 2022;41(12):979-984. doi:10.1097/INF.0000000000003715
<b>22</b>	Article	Pizzuto DA, Buonsenso D, Morello R, et al. Lung perfusion assessment in children with long-COVID: A pilot study. <i>Pediatr Pulmonol.</i> 2023;58(7):2059-2067. doi:10.1002/ppul.26432
<b>23</b>	Article	Gräger S, Pfirschke R, Lorenz M, et al. Lung ultrasound in children and adolescents with long-term effects of COVID-19: Initial results. <i>Front Pediatr.</i> 2023;11:1112881. Published 2023 Mar 24. doi:10.3389/fped.2023.1112881
<b>24</b>	Article	Morello R, Mariani F, Mastrantoni L, et al. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. <i>EClinicalMedicine.</i> 2023;59:101961. doi:10.1016/j.eclinm.2023.101961
<b>25</b>	Article	Atchison CJ, Whitaker M, Donnelly CA, et al. Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people: a large community cross-sectional study in England. <i>Arch Dis Child.</i> 2023;108(7):e12. doi:10.1136/archdischild-2022-325152
<b>26</b>	Article	Pinto Pereira SM, Nugawela MD, Rojas NK, et al. Post-COVID-19 condition at 6 months and COVID-19 vaccination in non-hospitalised children and young people. <i>Arch Dis Child.</i> 2023;108(4):289-295. doi:10.1136/archdischild-2022-324656
<b>27</b>	Article	Selvakumar J, Havdal LB, Drevvatne M, et al. Prevalence and Characteristics Associated With Post-COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults. <i>JAMA Netw Open.</i> 2023;6(3):e235763. Published 2023 Mar 1. doi:10.1001/jamanetworkopen.2023.5763
<b>28</b>	Article	Strawn JR, Mills JA, Schroeder HK, Neptune ZA, Specht A, Keeshin SW. The Impact of COVID-19 Infection and Characterization of Long COVID in Adolescents With Anxiety Disorders: A Prospective Longitudinal Study. <i>J Am Acad Child Adolesc Psychiatry.</i> 2023;62(7):707-709. doi:10.1016/j.jaac.2022.12.027
<b>29</b>	Article	Alsagheir A, Amer S, Alzubaidi L, Alenezi F, Alamaa T, Asiri A. A National Survey of Children, Adults, and the Elderly in the Fourth Wave of the COVID-19 Pandemic to Compare Acute and Post-COVID-19 Conditions in Saudi Arabia. <i>J Clin Med.</i> 2023;12(6):2242. Published 2023 Mar 14. doi:10.3390/jcm12062242

30	Article	Heiss R, Tan L, Schmidt S, et al. Pulmonary Dysfunction after Pediatric COVID-19. <i>Radiology</i> . 2023;306(3):e221250. doi:10.1148/radiol.221250
31	Article	Baptista de Lima J, Salazar L, Fernandes A, Teixeira C, Marques L, Afonso C. Long COVID in Children and Adolescents: A Retrospective Study in a Pediatric Cohort. <i>Pediatr Infect Dis J</i> . 2023;42(4):e109-e111. doi:10.1097/INF.0000000000003829
32	Article	Bogusławski S, Strzelak A, Gajko K, et al. The outcomes of COVID-19 pneumonia in children-clinical, radiographic, and pulmonary function assessment. <i>Pediatr Pulmonol</i> . 2023;58(4):1042-1050. doi:10.1002/ppul.26291
33	Article	Adler L, Israel M, Yehoshua I, et al. Long COVID symptoms in Israeli children with and without a history of SARS-CoV-2 infection: a cross-sectional study. <i>BMJ Open</i> . 2023;13(2):e064155. Published 2023 Feb 21. doi:10.1136/bmjopen-2022-064155
34	Article	Goretzki SC, Brasseler M, Dogan B, et al. High Prevalence of Alternative Diagnoses in Children and Adolescents with Suspected Long COVID-A Single Center Cohort Study. <i>Viruses</i> . 2023;15(2):579. Published 2023 Feb 20. doi:10.3390/v15020579
35	Article	Stephenson T, Pinto Pereira SM, Nugawela MD, et al. Long COVID-six months of prospective follow-up of changes in symptom profiles of non-hospitalised children and young people after SARS-CoV-2 testing: A national matched cohort study (The CLoCk) study. <i>PLoS One</i> . 2023;18(3):e0277704. Published 2023 Mar 6. doi:10.1371/journal.pone.0277704
36	Article	Katsuta T, Aizawa Y, Shoji K, et al. Acute and Postacute Clinical Characteristics of Coronavirus Disease 2019 in Children in Japan. <i>Pediatr Infect Dis J</i> . 2023;42(3):240-246. doi:10.1097/INF.0000000000003792
37	Article	Güven D, Buluş AD. Clinical and laboratory predictors of long-COVID in children: a single center retrospective study. <i>Eur Rev Med Pharmacol Sci</i> . 2022;26(20):7695-7704. doi:10.26355/eurrev_202210_30046
38	Article	Seery V, Raiden S, Penedo JMG, et al. Persistent symptoms after COVID-19 in children and adolescents from Argentina. <i>Int J Infect Dis</i> . 2023;129:49-56. doi:10.1016/j.ijid.2023.01.031
39	Article	Sakurada Y, Otsuka Y, Tokumasu K, et al. Trends in Long COVID Symptoms in Japanese Teenage Patients. <i>Medicina (Kaunas)</i> . 2023;59(2):261. Published 2023 Jan 29. doi:10.3390/medicina59020261
40	Article	Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. <i>BMJ</i> . 2023;380:e072529. Published 2023 Jan 11. doi:10.1136/bmj-2022-072529
41	Article	Buonsenso D, Pazukhina E, Gentili C, et al. The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy. <i>J Clin Med</i> . 2022;11(22):6772. Published 2022 Nov 16.

		doi:10.3390/jcm11226772
42	Article	Sommen SL, Havdal LB, Selvakumar J, et al. Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19. <i>Front Immunol.</i> 2023;13:1081718. Published 2023 Jan 6. doi:10.3389/fimmu.2022.1081718
43	Article	Jamaica Balderas LMDC, Navarro Fernández A, Dragustinovis Garza SA, et al. Long COVID in children and adolescents: COVID-19 follow-up results in third-level pediatric hospital. <i>Front Pediatr.</i> 2023;11:1016394. Published 2023 Jan 30. doi:10.3389/fped.2023.1016394
44	Article	Horikoshi Y, Shibata M, Funakoshi H, Baba S, Miyama S. Post coronavirus disease 2019 condition in children at a children's hospital in Japan. <i>Pediatr Int.</i> 2023;65(1):e15458. doi:10.1111/ped.15458
45	Article	Hicks SD. Comparison of Symptom Duration Between Children With SARS-CoV-2 and Peers With Other Viral Illnesses During the COVID-19 Pandemic [published online ahead of print, 2023 Feb 7]. <i>Clin Pediatr (Phila).</i> 2023;99228231152840. doi:10.1177/00099228231152840
46	Article	Haneef R, Fayad M, Fouillet A, et al. Direct impact of COVID-19 by estimating disability-adjusted life years at national level in France in 2020. <i>PLoS One.</i> 2023;18(1):e0280990. Published 2023 Jan 24. doi:10.1371/journal.pone.0280990
47	Article	Roessler M, Tesch F, Batram M, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany. <i>PLoS Med.</i> 2022;19(11):e1004122. Published 2022 Nov 10. doi:10.1371/journal.pmed.1004122
48	Article	Garazzino S, Denina M, Pruccoli G, Funicello E, Ramenghi U, Fagioli F. Long COVID-19/post-COVID condition in children: do we all speak the same language?. <i>Ital J Pediatr.</i> 2023;49(1):12. Published 2023 Jan 20. doi:10.1186/s13052-023-01417-8
49	Article	Walter N, Rupp M, Lang S, et al. A Comprehensive Report of German Nationwide Inpatient Data on the Post-COVID-19 Syndrome Including Annual Direct Healthcare Costs. <i>Viruses.</i> 2022;14(12):2600. Published 2022 Nov 22. doi:10.3390/v14122600
50	Article	Valenzuela G, Alarcón-Andrade G, Schulze-Schiapacasse C, et al. Short-term complications and post-acute sequelae in hospitalized paediatric patients with COVID-19 and obesity: A multicenter cohort study. <i>Pediatr Obes.</i> 2023;18(2):e12980. doi:10.1111/ijpo.12980
51	Article	Nugawela MD, Stephenson T, Shafran R, et al. Predictive model for long COVID in children 3 months after a SARS-CoV-2 PCR test. <i>BMC Med.</i> 2022;20(1):465. Published 2022 Nov 30. doi:10.1186/s12916-022-02664-y

52	Article	Kostev K, Smith L, Koyanagi A, Konrad M, Jacob L. Post-COVID-19 conditions in children and adolescents diagnosed with COVID-19 [published online ahead of print, 2022 May 14]. <i>Pediatr Res.</i> 2022;1-6. doi:10.1038/s41390-022-02111-x
53	Article	Buonsenso D, Valentini P, De Rose C, et al. Recovering or Persisting: The Immunopathological Features of SARS-CoV-2 Infection in Children. <i>J Clin Med.</i> 2022;11(15):4363. Published 2022 Jul 27. doi:10.3390/jcm11154363
54	Article	Brasseler M, Schönecker A, Steindor M, et al. Development of restrictive eating disorders in children and adolescents with long-COVID-associated smell and taste dysfunction. <i>Front Pediatr.</i> 2022;10:1022669. Published 2022 Nov 24. doi:10.3389/fped.2022.1022669
55	Article	Dumont R, Nehme M, Lorthe E, et al. Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study. <i>BMJ Open.</i> 2022;12(11):e063504. Published 2022 Nov 21. doi:10.1136/bmjopen-2022-063504
56	Article	Uysal B, Akça T, Akacı O, Uysal F. The Prevalence of Post-COVID-19 Hypertension in Children. <i>Clin Pediatr (Phila).</i> 2022;61(7):453-460. doi:10.1177/00099228221085346
57	Article	Dumont R, Richard V, Lorthe E, et al. A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents. <i>Nat Commun.</i> 2022;13(1):7086. Published 2022 Nov 29. doi:10.1038/s41467-022-34616-8
58	Article	Kikkenborg Berg S, Palm P, Nygaard U, et al. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. <i>Lancet Child Adolesc Health.</i> 2022;6(9):614-623. doi:10.1016/S2352-4642(22)00154-7
59	Article	Doshi JA, Sheils NE, Buresh J, et al. SARS-CoV-2 Sequelae and Postdischarge Health Care Visits Over 5 Months Follow-up Among Children Hospitalized for COVID-19 or MIS-C. <i>Pediatr Infect Dis J.</i> 2022;41(12):e513-e516. doi:10.1097/INF.0000000000003692
60	Article	Donnachie E, Hapfelmeier A, Linde K, et al. Incidence of post-COVID syndrome and associated symptoms in outpatient care in Bavaria, Germany: a retrospective cohort study using routinely collected claims data. <i>BMJ Open.</i> 2022;12(9):e064979. Published 2022 Sep 22. doi:10.1136/bmjopen-2022-064979
61	Article	Ng R, Vargas G, Jashar DT, Morrow A, Malone LA. Neurocognitive and Psychosocial Characteristics of Pediatric Patients With Post-Acute/Long-COVID: A Retrospective Clinical Case Series. <i>Arch Clin Neuropsychol.</i> 2022;37(8):1633-1643. doi:10.1093/arclin/acac056
62	Article	Messiah SE, Xie L, Mathew MS, et al. Comparison of Long-Term Complications of COVID-19 Illness among a Diverse Sample of Children by MIS-C Status. <i>Int J Environ Res Public Health.</i> 2022;19(20):13382. Published 2022 Oct 17.

		doi:10.3390/ijerph192013382
63	Article	Buchhorn R. Dysautonomia in Children with Post-Acute Sequelae of Coronavirus 2019 Disease and/or Vaccination. <i>Vaccines (Basel)</i> . 2022;10(10):1686. Published 2022 Oct 9. doi:10.3390/vaccines10101686
64	Article	Knoke L, Schlegtendal A, Maier C, Eitner L, Lücke T, Brinkmann F. Pulmonary Function and Long-Term Respiratory Symptoms in Children and Adolescents After COVID-19. <i>Front Pediatr</i> . 2022;10:851008. Published 2022 Apr 25. doi:10.3389/fped.2022.851008
65	Article	Di Gennaro L, Valentini P, Sorrentino S, et al. Extended coagulation profile of children with Long Covid: a prospective study. <i>Sci Rep</i> . 2022;12(1):18392. Published 2022 Nov 1. doi:10.1038/s41598-022-23168-y
66	Article	Koumpias AM, Schwartzman D, Fleming O. Long-haul COVID: healthcare utilization and medical expenditures 6 months post-diagnosis. <i>BMC Health Serv Res</i> . 2022;22(1):1010. Published 2022 Aug 8. doi:10.1186/s12913-022-08387-3
67	Article	Blankenburg J, Wekenborg MK, Reichert J, et al. Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic. <i>Sci Rep</i> . 2022;12(1):2246. Published 2022 Feb 10. doi:10.1038/s41598-022-06166-y
68	Article	Funk AL, Kuppermann N, Florin TA, et al. Post-COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection [published correction appears in <i>JAMA Netw Open</i> . 2022 Aug 1;5(8):e2231131]. <i>JAMA Netw Open</i> . 2022;5(7):e2223253. Published 2022 Jul 1. doi:10.1001/jamanetworkopen.2022.23253
69	Article	Merzon E, Weiss M, Krone B, et al. Clinical and Socio-Demographic Variables Associated with the Diagnosis of Long COVID Syndrome in Youth: A Population-Based Study. <i>Int J Environ Res Public Health</i> . 2022;19(10):5993. Published 2022 May 15. doi:10.3390/ijerph19105993
70	Article	Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. <i>JAMA Pediatr</i> . 2022;176(10):1000-1009. doi:10.1001/jamapediatrics.2022.2800
71	Article	Buonsenso D, Pujol FE, Munblit D, Pata D, McFarland S, Simpson FK. Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: a survey of 510 children. <i>Future Microbiol</i> . 2022;17(8):577-588. doi:10.2217/fmb-2021-0285
72	Article	Messiah SE, Hao T, DeSantis SM, et al. Comparison of Persistent Symptoms Following SARS-CoV-2 Infection by Antibody Status in Nonhospitalized Children and Adolescents. <i>Pediatr Infect Dis J</i> . 2022;41(10):e409-e417. doi:10.1097/INF.0000000000003653

73	Article	Haddad A, Janda A, Renk H, et al. Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational cohort study. <i>EBioMedicine</i> . 2022;84:104245. doi:10.1016/j.ebiom.2022.104245
74	Article	Saini L, Krishna D, Tiwari S, et al. Post-COVID-19 Immune-Mediated Neurological Complications in Children: An Ambispective Study. <i>Pediatr Neurol</i> . 2022;136:20-27. doi:10.1016/j.pediatrneurol.2022.06.010
75	Article	Helmsdal G, Hanusson KD, Kristiansen MF, et al. Long COVID in the Long Run-23-Month Follow-up Study of Persistent Symptoms. <i>Open Forum Infect Dis</i> . 2022;9(7):ofac270. Published 2022 Jun 6. doi:10.1093/ofid/ofac270
76	Article	Guido CA, Lucidi F, Midulla F, et al. Neurological and psychological effects of long COVID in a young population: A cross-sectional study. <i>Front Neurol</i> . 2022;13:925144. Published 2022 Aug 17. doi:10.3389/fneur.2022.925144
77	Article	Tarantino S, Graziano S, Carducci C, Giampaolo R, Grimaldi Capitello T. Cognitive Difficulties, Psychological Symptoms, and Long Lasting Somatic Complaints in Adolescents with Previous SARS-CoV-2 Infection: A Telehealth Cross-Sectional Pilot Study. <i>Brain Sci</i> . 2022;12(8):969. Published 2022 Jul 23. doi:10.3390/brainsci12080969
78	Article	Asadi-Pooya AA, Nemati M, Nemati H. 'Long COVID': Symptom persistence in children hospitalised for COVID-19. <i>J Paediatr Child Health</i> . 2022;58(10):1836-1840. doi:10.1111/jpc.16120
79	Article	Kuczborska K, Buda P, Książyk J. Long-COVID in immunocompromised children. <i>Eur J Pediatr</i> . 2022;181(9):3501-3509. doi:10.1007/s00431-022-04561-1
80	Article	Palacios S, Krivchenia K, Eisner M, et al. Long-term pulmonary sequelae in adolescents post-SARS-CoV-2 infection. <i>Pediatr Pulmonol</i> . 2022;57(10):2455-2463. doi:10.1002/ppul.26059
81	Article	Bloise S, Isoldi S, Marcellino A, et al. Clinical picture and long-term symptoms of SARS-CoV-2 infection in an Italian pediatric population. <i>Ital J Pediatr</i> . 2022;48(1):79. Published 2022 May 21. doi:10.1186/s13052-022-01270-1
82	Article	Petersen MS, Kristiansen MF, Hanusson KD, et al. Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months' follow-up. <i>Int J Infect Dis</i> . 2022;122:437-441. doi:10.1016/j.ijid.2022.06.031
83	Article	Bode SFN, Haendly M, Fabricius D, et al. Pulmonary Function and Persistent Clinical Symptoms in Children and Their Parents 12 Months After Mild SARS-CoV-2 Infection. <i>Front Pediatr</i> . 2022;10:894331. Published 2022 Jun 30. doi:10.3389/fped.2022.894331
84	Article	Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). <i>BMC Med</i> .



		2022;20(1):244. Published 2022 Jul 6. doi:10.1186/s12916-022-02448-4
85	Article	Öztürk GK, Beken B, Doğan S, Akar HH. Pulmonary function tests in the follow-up of children with COVID-19. <i>Eur J Pediatr.</i> 2022;181(7):2839-2847. doi:10.1007/s00431-022-04493-w
86	Article	Buonsenso D, Munblit D, Pazukhina E, et al. Post-COVID Condition in Adults and Children Living in the Same Household in Italy: A Prospective Cohort Study Using the ISARIC Global Follow-Up Protocol. <i>Front Pediatr.</i> 2022;10:834875. Published 2022 Apr 21. doi:10.3389/fped.2022.834875
87	Article	Bergia M, Sanchez-Marcos E, Gonzalez-Haba B, et al. Comparative study shows that 1 in 7 Spanish children with COVID-19 symptoms were still experiencing issues after 12 weeks. <i>Acta Paediatr.</i> 2022;111(8):1573-1582. doi:10.1111/apa.16368
88	Article	Burgos-Blasco B, Güemes-Villahoz N, Morales-Fernandez L, et al. Retinal nerve fibre layer and ganglion cell layer changes in children who recovered from COVID-19: a cohort study. <i>Arch Dis Child.</i> 2022;107(2):175-179. doi:10.1136/archdischild-2021-321803
89	Article	Trapani G, Verlato G, Bertino E, et al. Long COVID-19 in children: an Italian cohort study. <i>Ital J Pediatr.</i> 2022;48(1):83. Published 2022 Jun 3. doi:10.1186/s13052-022-01282-x
90	Article	Doležalová K, Tuková J, Pohunek P. The respiratory consequences of COVID-19 lasted for a median of 4 months in a cohort of children aged 2-18 years of age. <i>Acta Paediatr.</i> 2022;111(6):1201-1206. doi:10.1111/apa.16297
91	Article	Kikkenborg Berg S, Dam Nielsen S, Nygaard U, et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. <i>Lancet Child Adolesc Health.</i> 2022;6(4):240-248. doi:10.1016/S2352-4642(22)00004-9
92	Article	Esmailzadeh, H., Sanaei Dashti, A., Mortazavi, N. et al. Persistent cough and asthma-like symptoms post COVID-19 hospitalization in children. <i>BMC Infect Dis</i> 22, 244 (2022). <a href="https://doi.org/10.1186/s12879-022-07252-2">https://doi.org/10.1186/s12879-022-07252-2</a>
93	Article	Akçay E, Çöp E, Dinç GS, et al. Loneliness, internalizing symptoms, and inflammatory markers in adolescent COVID-19 survivors. <i>Child Care Health Dev.</i> 2022;48(6):1112-1121. doi:10.1111/cch.13043
94	Article	Maddux AB, Berbert L, Young CC, et al. Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C. <i>Pediatrics.</i> 2022;150(3):e2022057798. doi:10.1542/peds.2022-057798
95	Article	Gonzalez-Aumatell A, Bovo MV, Carreras-Abad C, et al. Social, Academic, and Health Status Impact of Long COVID on Children and Young People: An Observational, Descriptive, and Longitudinal Cohort Study. <i>Children (Basel).</i> 2022;9(11):1677. Published 2022 Oct 31. doi:10.3390/children9111677

96	Article	Lorman V, Rao S, Jhaveri R, et al. Understanding pediatric long COVID using a tree-based scan statistic approach: an EHR-based cohort study from the RECOVER Program. <i>JAMIA Open</i> . 2023;6(1):o0ad016. Published 2023 Mar 14. doi:10.1093/jamiaopen/o0ad016
97	Article	Sabatino J, Di Chiara C, Di Candia A, et al. Mid- and Long-Term Atrio-Ventricular Functional Changes in Children after Recovery from COVID-19. <i>J Clin Med</i> . 2022;12(1):186. Published 2022 Dec 26. doi:10.3390/jcm12010186
98	Article	Buonsenso D, Martino L, Morello R, De Rose C, Valentini P. Chronic Olfactory Dysfunction in Children with Long COVID: A Retrospective Study. <i>Children (Basel)</i> . 2022;9(8):1251. Published 2022 Aug 19. doi:10.3390/children9081251
99	Article	Erol N, Alpınar A, Erol C, Sari E, Alkan K. Intriguing new faces of Covid-19: persisting clinical symptoms and cardiac effects in children. <i>Cardiol Young</i> . 2022;32(7):1085-1091. doi:10.1017/S1047951121003693
<b>2b. Clinical trials protocols</b>		
	<b>Trial ID</b>	<b>Study title</b>
1	NCT05722717	Genetic Risk Factors for Multi-system Inflammatory Syndrome in Children and Pediatric Post COVID Condition (GRIP)
2	NCT05793723	Long-term Respiratory Complications in Infants With Perinatal COVID-19
3	NCT05638724	Munich Long COVID Registry Study for Children, Adolescents and Adults (MLC-R)
4	NCT05633472	The Roles of Vitamin D and Microbiome in Children With Post-acute COVID-19 Syndromes (PACS) and Long COVID
5	NCT05817006	Research of the Long-COVID-19 Syndrome in the Children
6	NCT05216549	Water and Land-based Exercise for Children With Post COVID-19 Condition
7	NCT05745974	Post COVID-19 Complications in Children
8	NCT05729217	Long COVID Symptoms in SARS-CoV-2-positive Children in China
9	NCT05799508	Consequences of COVID-19 Infection for Child Health and Wellbeing: Protocol for a Prospective, Observational, Longitudinal Study in Children

<b>10</b>	NCT05582512	Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan
<b>11</b>	NCT05747534	AT1001 for the Treatment of Long COVID
<b>12</b>	NCT05705154	Connecting Breath and Mind for CYP With Long COVID
<b>13</b>	NCT05566392	Longterm Influence of Pediatric Long COVID Syndrome
<b>14</b>	NCT05445531	Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19
<b>15</b>	DRKS00029354	"coverCHILD Telemonitoring"
<b>16</b>	DRKS00028742	Post COVID Kids Bavaria (PoCO) study on long-term effects of coronavirus infections in children and adolescents in Bavaria: detection and early treatment of sequelae
<b>17</b>	CTRI/2022/07/043846	A study to understand the changes in lung after corona virus infection in children undergoing heart surgery, using ultrasound examination.
<b>18</b>	DRKS00028523	Long COVID in Children
<b>19</b>	ISRCTN99910769	The impact of COVID-19 infection in newborns or in pregnancy on children's development at 18-24 months
<b>20</b>	DRKS00028963	Telemedicine-assisted rehabilitation after Covid-19 in children
<b>21</b>	TCTR20220510005	The study to follow-up and provide holistic healthcare in children and adolescents (aged 6 months-18 years) following the COVID-19 infection
<b>22</b>	DRKS00028539	Determination of aerosol particle number and aerosol particle size distribution in exhaled air of healthy children as well as children with respiratory tract infections, especially also children with and after SARS-CoV2 infection/Covid-19.
<b>Total number of references - 212</b>		

### 3. THE LONG LIST OF OUTCOMES USED IN POST-COVID-19 CONDITION STUDIES.

OUTCOME DOMAIN (PER COMET TAXONOMY*)	OUTCOME	N = 1097
1. MORTALITY/SURVIVAL	DEAD AFTER DISCHARGE	
1. MORTALITY/SURVIVAL	MORBIDITY	

1. MORTALITY/SURVIVAL	MORTALITY	3
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	ABNORMAL LAB RESULT (D-DIMER)	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	COAGULATION ABNORMALITY	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	COAGULOPATHY AFTER COVID-19	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	COVID-19-ASSOCIATED THROMBOSIS	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	DISSEMINATED INTRAVASCULAR COAGULATION	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	ENLARGED LYMPH NODES	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	BLOOD MARKERS CORRELATION WITH FOT INDICES	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	HEMOGLOBIN	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	INCREASED/DECREASED/NORMAL RESULT	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	LABORATORY ASSESSMENT	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	LABORATORY CHANGES	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	LEUCOCYTES $<4 \times 10^9/L$	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	LEUKOCYTES	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	LOW NEUTROPHILS	

2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	LYMPHADENOPATHY	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	LYMPHOCYTES $<1.2 \times 10^9/L$	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	NEGATIVE D-DIMERS	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	PBMC	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	SWOLLEN LYMPH GLANDS	
2. BLOOD AND LYMPHATIC SYSTEM OUTCOMES	THROMBOCYTES	20
3. CARDIAC OUTCOMES	ABNORMAL FINDINGS	
3. CARDIAC OUTCOMES	BLOOD PRESSURE	
3. CARDIAC OUTCOMES	CARDIAC FUNCTION	
3. CARDIAC OUTCOMES	CARDIAC FUNCTION AND EJECTION FRACTION CHANGES	
3. CARDIAC OUTCOMES	CARDIAC PALPITATIONS	
3. CARDIAC OUTCOMES	CARDIAL ABNORMALITIES	
3. CARDIAC OUTCOMES	CARDIOVASCULAR COMPLICATIONS	
3. CARDIAC OUTCOMES	CARDIOVASCULAR SYMPTOMS	
3. CARDIAC OUTCOMES	CARDIOVASCULAR SYSTEM	
3. CARDIAC OUTCOMES	CARDITIS DUE TO VIRUSES	
3. CARDIAC OUTCOMES	CORONARY ARTERY ABNORMALITIES	
3. CARDIAC OUTCOMES	DAMAGE TO THE HEART	
3. CARDIAC OUTCOMES	DIFFERENCE IN RELATIVE WALL THICKNESS	
3. CARDIAC OUTCOMES	DIFFERENCE IN TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION VALUES	
3. CARDIAC OUTCOMES	ELEVATED PULSE	
3. CARDIAC OUTCOMES	HEART FAILURE	

3. CARDIAC OUTCOMES	HEART MURMURS	
3. CARDIAC OUTCOMES	HEART POUNDING OR RACING	
3. CARDIAC OUTCOMES	HEART RATE ABNORMALITY	
3. CARDIAC OUTCOMES	HEART RHYTHM DISTURBANCES	
3. CARDIAC OUTCOMES	HIGHEST HEART RATE	
3. CARDIAC OUTCOMES	HYPOTENSION	
3. CARDIAC OUTCOMES	INTERVALS	
3. CARDIAC OUTCOMES	LEFT VENTRICULAR POSTERIOR WALL DIAMETER	
3. CARDIAC OUTCOMES	LOWEST HEART RATE	
3. CARDIAC OUTCOMES	MAXIMAL PULSE WAS LOWER THAN THE AGE-SPECIFIC MEAN	
3. CARDIAC OUTCOMES	MILD LATERAL WALL THICKENING	
3. CARDIAC OUTCOMES	MYOCARDIAL INFARCTION	
3. CARDIAC OUTCOMES	MYOCARDITIS	
3. CARDIAC OUTCOMES	MYOCARDITIS AFTER COVID-19	
3. CARDIAC OUTCOMES	NORMAL LEFT VENTRICULAR EJECTION FRACTION AND THE ABSENCE OF PULMONARY HYPERTENSION	
3. CARDIAC OUTCOMES	ORTHOSTATIC INTOLERANCE	
3. CARDIAC OUTCOMES	OTHER CARDIAC ARRHYTHMIAS	
3. CARDIAC OUTCOMES	PAINS IN HEART OR CHEST	
3. CARDIAC OUTCOMES	PALPITATION	
3. CARDIAC OUTCOMES	PALPITATION±CHEST PAIN	
3. CARDIAC OUTCOMES	PALPITATIONS	
3. CARDIAC OUTCOMES	PALPITATIONS (HEART RACING)	
3. CARDIAC OUTCOMES	PALPITATIONS / TACHYCARDIA	
3. CARDIAC OUTCOMES	PERICARDITIS	
3. CARDIAC OUTCOMES	PULMONARY HYPERTENSION	
3. CARDIAC OUTCOMES	RHYTHMS	

3. CARDIAC OUTCOMES	RIGHT VENTRICULAR SYSTOLIC FUNCTION (IN PATIENTS W/BIVENTRICULAR PHYSIOLOGY)	
3. CARDIAC OUTCOMES	SEVERE POST-COVID-19 COMPLICATIONS	
3. CARDIAC OUTCOMES	SIGNIFICANT TACHYCARDIA FOR AGE	
3. CARDIAC OUTCOMES	TACHYCARDIA	
3. CARDIAC OUTCOMES	TACHYCARDIA/PALPITATION	
3. CARDIAC OUTCOMES	TRANSIENTLY ELEVATED TROPONIN LEVELS	
3. CARDIAC OUTCOMES	TRICUSPID REGURGITATION SEVERITY	
3. CARDIAC OUTCOMES	TYPE(S) AND NUMBER OF PULMONARY HYPERTENSION TARGETED THERAPIES	
3. CARDIAC OUTCOMES	VARIATIONS IN HEART RATE	
3. CARDIAC OUTCOMES	VARIATIONS IN HEART RATE (TACHYCARDIA OR BRADYCARDIA)	
3. CARDIAC OUTCOMES	VELOCITY	
3. CARDIAC OUTCOMES	VOLTAGES	54
4. CONGENITAL, FAMILIAL AND GENETIC OUTCOMES	GENETIC PREDISPOSITION	
4. CONGENITAL, FAMILIAL AND GENETIC OUTCOMES	GENETIC PREDISPOSITION IN CHILDREN TO COVID-19 LATE COMPLICATIONS	
4. CONGENITAL, FAMILIAL AND GENETIC OUTCOMES	HUMAN AND VIRAL GENETIC MARKERS	3
5. ENDOCRINE OUTCOMES	TYPE 1 DIABETES AFTER COVID-19	
5. ENDOCRINE OUTCOMES	TYPE 2 DIABETES AFTER COVID-19	
5. ENDOCRINE OUTCOMES	TYPE 2 DIABETES	3
6. EAR AND LABYRINTH OUTCOMES	CHANGE IN HEARING/RINGING IN EARS	
6. EAR AND LABYRINTH OUTCOMES	EAR FULLNESS	
6. EAR AND LABYRINTH OUTCOMES	EAR PAIN	
6. EAR AND LABYRINTH OUTCOMES	EAR PAIN (OTALGIA)	
6. EAR AND LABYRINTH OUTCOMES	EAR SYMPTOMS	

6. EAR AND LABYRINTH OUTCOMES	EARACHE OR RINGING IN EARS	
6. EAR AND LABYRINTH OUTCOMES	HEARING DEFICIT	
6. EAR AND LABYRINTH OUTCOMES	HEARING LOSS/TINNITUS	
6. EAR AND LABYRINTH OUTCOMES	HEARING PROBLEMS	
6. EAR AND LABYRINTH OUTCOMES	LOSS OF HEAR	
6. EAR AND LABYRINTH OUTCOMES	RINGING IN EARS (TINNITUS)	
6. EAR AND LABYRINTH OUTCOMES	TINNITUS	
6. EAR AND LABYRINTH OUTCOMES	VERTIGO	
6. EAR AND LABYRINTH OUTCOMES	VERTIGO/WORLD SPINNING	14
7. EYE OUTCOMES	AVOIDING BRIGHT LIGHT (PHOTOPHOBIA)	
7. EYE OUTCOMES	BILATERAL CONJUNCTIVITIS	
7. EYE OUTCOMES	BILATERAL CONJUNCTIVITIS (IF YES, PURULENT/NON-PURULENT)	
7. EYE OUTCOMES	BLURRED VISION	
7. EYE OUTCOMES	CHANGES IN VISION	
7. EYE OUTCOMES	CONJUNCTIVITIS	
7. EYE OUTCOMES	DRY EYES	
7. EYE OUTCOMES	EYE PAIN	
7. EYE OUTCOMES	EYE SORENESS	
7. EYE OUTCOMES	EYE-SORENESS/DISCOMFORT (LIGHT SENSITIVITY/EXCESSIVE TEARS/PINK/RED EYE)	
7. EYE OUTCOMES	FLASHES OF LIGHT (PHOTOPSIA)	
7. EYE OUTCOMES	FOVEAL AVASCULAR ZONE: AREA	
7. EYE OUTCOMES	FOVEAL AVASCULAR ZONE: CIRCULARITY	
7. EYE OUTCOMES	FOVEAL AVASCULAR ZONE: PERIMETER	
7. EYE OUTCOMES	HIGH FLUX INDEX	
7. EYE OUTCOMES	INCREASE IN MACULAR PERFUSION DENSITY	
7. EYE OUTCOMES	INCREASE IN RETINAL VESSEL DENSITY	



7. EYE OUTCOMES	INFERIOR FLUX INDEX	
7. EYE OUTCOMES	INFERIOR PERIPAPILLARY PERFUSION DENSITY	
7. EYE OUTCOMES	MACULAR PERFUSION DENSITY: CENTRAL	
7. EYE OUTCOMES	MACULAR PERFUSION DENSITY: INNER RING	
7. EYE OUTCOMES	MACULAR PERFUSION DENSITY: OUTER RING	
7. EYE OUTCOMES	NASAL FLUX INDEX	
7. EYE OUTCOMES	NASAL PERIPAPILLARY PERFUSION DENSITY	
7. EYE OUTCOMES	OCULAR FINDINGS	
7. EYE OUTCOMES	PHOTOPHOBIA	
7. EYE OUTCOMES	PROBLEMS SEEING/ BLURRED VISION	
7. EYE OUTCOMES	PROBLEMS SEEING/BLURRED VISION	
7. EYE OUTCOMES	RED EYE SYNDROME	
7. EYE OUTCOMES	SUPERIOR FLUX INDEX	
7. EYE OUTCOMES	SUPERIOR PERIPAPILLARY PERFUSION DENSITY	
7. EYE OUTCOMES	TEMPORAL PERIPAPILLARY PERFUSION DENSITY	
7. EYE OUTCOMES	UNUSUAL EYE-SORENESS	
7. EYE OUTCOMES	VESSEL DENSITY: CENTRAL	
7. EYE OUTCOMES	VESSEL DENSITY: FULL AREA	
7. EYE OUTCOMES	VESSEL DENSITY: INNER RING	
7. EYE OUTCOMES	VESSEL DENSITY: OUTER RING	
7. EYE OUTCOMES	VISUAL ACUITY/HEARING PROBLEMS	
7. EYE OUTCOMES	VISUAL BLURRING	
7. EYE OUTCOMES	VISUAL DEFICIT	
7. EYE OUTCOMES	VISUAL DISTURBANCES	41
8. GASTROINTESTINAL OUTCOMES	ABDOMINAL DISCOMFORT	
8. GASTROINTESTINAL OUTCOMES	ABDOMINAL PAIN	

8. GASTROINTESTINAL OUTCOMES	ABDOMINAL PAIN/STOMACH ACHE ( <i>MILD AND TOLERABLE-MODERATE-SEVERE AND INCAPACITATING</i> )	
8. GASTROINTESTINAL OUTCOMES	BLOATING	
8. GASTROINTESTINAL OUTCOMES	BOWEL INCONTINENCE	
8. GASTROINTESTINAL OUTCOMES	CHANGE IN BOWEL HABITS	
8. GASTROINTESTINAL OUTCOMES	COLITIS/DIARRHOEA	
8. GASTROINTESTINAL OUTCOMES	CONSTIPATION	
8. GASTROINTESTINAL OUTCOMES	DIARRHEA	
8. GASTROINTESTINAL OUTCOMES	DIARRHOEA/VOMITING	
8. GASTROINTESTINAL OUTCOMES	DYSPHAGIA	
8. GASTROINTESTINAL OUTCOMES	FECES	
8. GASTROINTESTINAL OUTCOMES	FEELING NAUSEOUS	
8. GASTROINTESTINAL OUTCOMES	FLATULENCE	
8. GASTROINTESTINAL OUTCOMES	GASTROINTESTINAL DISORDERS	
8. GASTROINTESTINAL OUTCOMES	GASTROINTESTINAL SYMPTOMS	
8. GASTROINTESTINAL OUTCOMES	HEARTBURN	
8. GASTROINTESTINAL OUTCOMES	INTUSSUSCEPTION	
8. GASTROINTESTINAL OUTCOMES	JAUNDICE	
8. GASTROINTESTINAL OUTCOMES	LOOSE STOOL	
8. GASTROINTESTINAL OUTCOMES	NAUSEA	
8. GASTROINTESTINAL OUTCOMES	NAUSEA OR UPSET STOMACH	
8. GASTROINTESTINAL OUTCOMES	PAIN ABDOMEN	
8. GASTROINTESTINAL OUTCOMES	PATTERNS OF INTESTINAL MICROBIOME	
8. GASTROINTESTINAL OUTCOMES	SKIPPING MEALS	
8. GASTROINTESTINAL OUTCOMES	STOMACH ACHE	
8. GASTROINTESTINAL OUTCOMES	STOMACH PAIN	
8. GASTROINTESTINAL OUTCOMES	STOMACH PAINS/CRAMPS	

8. GASTROINTESTINAL OUTCOMES	STOMACH/ ABDOMINAL PAIN	
8. GASTROINTESTINAL OUTCOMES	STOMACH/ABDOMINAL PAIN	
8. GASTROINTESTINAL OUTCOMES	STOMACHACHE	
8. GASTROINTESTINAL OUTCOMES	TENDERNESS IN ABDOMEN	
8. GASTROINTESTINAL OUTCOMES	TUMMY ACHE	
8. GASTROINTESTINAL OUTCOMES	UNUSUAL ABDOMINAL PAIN	
8. GASTROINTESTINAL OUTCOMES	VOMITING	
8. GASTROINTESTINAL OUTCOMES	VOMITING AND ABDOMINAL PAIN	
8. GASTROINTESTINAL OUTCOMES	VOMITING/NAUSEA	
8. GASTROINTESTINAL OUTCOMES	VOMITS	38
9. GENERAL OUTCOMES	ABNORMAL BODY MOVEMENTS	
9. GENERAL OUTCOMES	ABNORMAL FINDINGS	
9. GENERAL OUTCOMES	ACUTE PAIN	
9. GENERAL OUTCOMES	ADDITIONAL BIOMARKER ANALYSIS	
9. GENERAL OUTCOMES	ANY CHRONIC MEDICAL ILLNESS/PROBLEM AFTER COVID-19	
9. GENERAL OUTCOMES	ASSESSMENT OF REHABILITATION	
9. GENERAL OUTCOMES	ASTHENIA	
9. GENERAL OUTCOMES	BODY ACHES	
9. GENERAL OUTCOMES	BODY PAIN	
9. GENERAL OUTCOMES	CAUSE OF RECENT FEVER (COVID-19, OTHER RESPIRATORY INFECTION (COUGH/COLD/SORE THROAT), TB, STOMACH INFECTION (DIARRHEA/VOMITING), URINARY INFECTION, OTHER, UNKNOWN, PREFER NOT TO SAY)	
9. GENERAL OUTCOMES	CHANGE IN SMELL	
9. GENERAL OUTCOMES	CHANGE IN TASTE	
9. GENERAL OUTCOMES	CHEST AND BACKACHE	
9. GENERAL OUTCOMES	CHEST TIGHTNESS	
9. GENERAL OUTCOMES	CHILD SYMPTOMS	

9. GENERAL OUTCOMES	CHILLS	
9. GENERAL OUTCOMES	CHILLS OR SHIVERS (FEEL TOO COLD)	
9. GENERAL OUTCOMES	CHRONIC FATIGUE	
9. GENERAL OUTCOMES	CHRONIC FATIGUE SYNDROME	
9. GENERAL OUTCOMES	CHRONIC FATIGUE SYNDROME-TYPE SYMPTOMS	
9. GENERAL OUTCOMES	CLINICAL OUTCOME	
9. GENERAL OUTCOMES	COMPLETE REMISSION	
9. GENERAL OUTCOMES	CONNECTEDNESS	
9. GENERAL OUTCOMES	COVID-19 ASSOCIATED SECONDARY DISEASES PREDICTORS	
9. GENERAL OUTCOMES	DAMAGE TO OTHER VITAL SYSTEMS WHICH CAUSED DEATH	
9. GENERAL OUTCOMES	DAYTIME SLEEPINESS	
9. GENERAL OUTCOMES	DECREASED APPETITE	
9. GENERAL OUTCOMES	DEMOGRAPHICS	
9. GENERAL OUTCOMES	DIAGNOSES	
9. GENERAL OUTCOMES	DIFFICULTY FALLING ASLEEP	
9. GENERAL OUTCOMES	DIFFICULTY SLEEPING	
9. GENERAL OUTCOMES	DIFFICULTY SWALLOWING	
9. GENERAL OUTCOMES	DISABILITY-ADJUSTED LIFE YEARS (DALY) LOST PER COVID-19 CASE	
9. GENERAL OUTCOMES	DISTANCE WALKED IN METERS AND % PREDICTED	
9. GENERAL OUTCOMES	DRY MOUTH	
9. GENERAL OUTCOMES	EASY FATIGABILITY	
9. GENERAL OUTCOMES	EXCESS SWEATING	
9. GENERAL OUTCOMES	EXCESSIVE FATIGUE	
9. GENERAL OUTCOMES	EXCESSIVE NIGHT SWEAT	
9. GENERAL OUTCOMES	EXCESSIVE SLEEPINESS	
9. GENERAL OUTCOMES	EXHAUSTION	

9. GENERAL OUTCOMES	FACTORS RELATED TO THE SEVERITY	
9. GENERAL OUTCOMES	FATIGUE	
9. GENERAL OUTCOMES	FATIGUE AFTER COVID-19 (LESS/THE SAME/MORE)	
9. GENERAL OUTCOMES	FATIGUE RELATED DISORDERS	
9. GENERAL OUTCOMES	FATIGUE/LOW ENERGY	
9. GENERAL OUTCOMES	FATIGUE/TIREDNESS	
9. GENERAL OUTCOMES	FEEL SLEEPY OR DROWSY	
9. GENERAL OUTCOMES	FEEL WEAK	
9. GENERAL OUTCOMES	FEELING RELAXED	
9. GENERAL OUTCOMES	FEVER	
9. GENERAL OUTCOMES	FEVER (WITHIN THE LAST 7 D, 1-2 WKS, >2-4 WKS, >1-2 MO, >2-3 MO, >3-6 MO SINCE DISCHARGE)	
9. GENERAL OUTCOMES	FEVER >38.5°C	
9. GENERAL OUTCOMES	GENERAL SYMPTOMS	
9. GENERAL OUTCOMES	HEAD CIRCUMFERENCE	
9. GENERAL OUTCOMES	HEALTH	
9. GENERAL OUTCOMES	HOT OR COLD SPELLS	
9. GENERAL OUTCOMES	HYPERSOMNIA	
9. GENERAL OUTCOMES	HYPOTHERMIA	
9. GENERAL OUTCOMES	ILLNESS RESOLUTION	
9. GENERAL OUTCOMES	IMAGING FINDING	
9. GENERAL OUTCOMES	INCREASED DAYTIME FATIGUE	
9. GENERAL OUTCOMES	INCREASED FATIGUE	
9. GENERAL OUTCOMES	INCREASED NEED FOR SLEEP	
9. GENERAL OUTCOMES	INCREASED SLEEP NEED	
9. GENERAL OUTCOMES	INSOMNIA	
9. GENERAL OUTCOMES	INSOMNIA (HARD TO FALL ASLEEP, HARD TO STAY ASLEEP)	

9. GENERAL OUTCOMES	LAB RESULTS OUT OF THE NORMAL RANGES	
9. GENERAL OUTCOMES	LABORATORY PARAMETERS	
9. GENERAL OUTCOMES	LACK OF A GOOD NIGHT'S SLEEP	
9. GENERAL OUTCOMES	LACK OF ENERGY	
9. GENERAL OUTCOMES	LENGTH	
9. GENERAL OUTCOMES	LENGTH OF COVID-19 SEQUELAE	
9. GENERAL OUTCOMES	LONG COVID SYMPTOMS	
9. GENERAL OUTCOMES	LONG COVID SYMPTOMS	
9. GENERAL OUTCOMES	LONG TERM OUTCOME (PREVALENCE AND RISK FACTORS OF LONG-LASTING COMPLICATION)	
9. GENERAL OUTCOMES	LONG-TERM CONSEQUENCES OF A COVID19 DISEASE (LONG-COVID)	
9. GENERAL OUTCOMES	LONG-TERM OUTCOMES OF COVID-19 IN PATIENTS DIAGNOSED WITH COVID-19	
9. GENERAL OUTCOMES	A LUMP IN YOUR THROAT	
9. GENERAL OUTCOMES	MALAISE	
9. GENERAL OUTCOMES	MALAISE/FATIGUE/EXHAUSTION	
9. GENERAL OUTCOMES	MEDICAL SEQUELAE	
9. GENERAL OUTCOMES	METALLIC TASTE	
9. GENERAL OUTCOMES	MIS	
9. GENERAL OUTCOMES	MULTIPLE ORGAN FAILURE	
9. GENERAL OUTCOMES	NEED OF HOSPITAL ADMISSION	
9. GENERAL OUTCOMES	NEED TO REST MORE	
9. GENERAL OUTCOMES	NEWLY DIAGNOSED DISEASES	
9. GENERAL OUTCOMES	NIGHT SWEATING	
9. GENERAL OUTCOMES	NONSPECIFIC PAIN	
9. GENERAL OUTCOMES	NOT ELSEWHERE CLASSIFIED	
9. GENERAL OUTCOMES	OEDEMA	
9. GENERAL OUTCOMES	ORGAN DAMAGE	

9. GENERAL OUTCOMES	ORGAN FUNCTION	
9. GENERAL OUTCOMES	ORGAN FUNCTION DAMAGE	
9. GENERAL OUTCOMES	ORGANIC SECONDARY OUTCOMES	
9. GENERAL OUTCOMES	OTHER CONDITION AFTER COVID-19	
9. GENERAL OUTCOMES	OTHER IMPORTANT SYMPTOMS	
9. GENERAL OUTCOMES	OTHER NEW SYMPTOMS	
9. GENERAL OUTCOMES	OTHER SYMPTOMS	
9. GENERAL OUTCOMES	OTHER SYMPTOMS (IF YES, DURATION)	
9. GENERAL OUTCOMES	OTHER SYMPTOMS OR COMPLAIN	
9. GENERAL OUTCOMES	PAIN	
9. GENERAL OUTCOMES	PAIN, NOT ELSEWHERE CLASSIFIED	
9. GENERAL OUTCOMES	PERSISTENT FATIGUE	
9. GENERAL OUTCOMES	POOR SLEEP QUALITY	
9. GENERAL OUTCOMES	POPULATION BASED DATA ON SPECTRUM AND RECOVERY FROM COVID-19 SYMPTOMS	
9. GENERAL OUTCOMES	POST-COVID	
9. GENERAL OUTCOMES	POSTVIRAL FATIGUE	
9. GENERAL OUTCOMES	PREDICTORS OF RECOVERY	
9. GENERAL OUTCOMES	PRIMARY SYMPTOMS	
9. GENERAL OUTCOMES	PROBLEM IN SECOND MONTH	
9. GENERAL OUTCOMES	PROBLEM IN THIRD MONTH	
9. GENERAL OUTCOMES	PROBLEM WITHIN 1 MONTH	
9. GENERAL OUTCOMES	PROBLEMS SWALLOWING OR CHEWING	
9. GENERAL OUTCOMES	PROBLEMS WITH HANDWRITING	
9. GENERAL OUTCOMES	RADIOLOGICAL ASSESSMENT	
9. GENERAL OUTCOMES	RADIOLOGICAL PARAMETERS	
9. GENERAL OUTCOMES	RECOVERY	

9. GENERAL OUTCOMES	RECURRENT PAIN IN THE BODY	
9. GENERAL OUTCOMES	RESTLESS SLEEP WITH INTERRUPTIONS	
9. GENERAL OUTCOMES	RISK FACTORS FOR MEDICAL SEQUELAE	
9. GENERAL OUTCOMES	RISK OF LATE COMPLICATIONS	
9. GENERAL OUTCOMES	SEVERITY OF SYMPTOMS	
9. GENERAL OUTCOMES	SHOCK	
9. GENERAL OUTCOMES	SHOCK / TOXIC SHOCK SYNDROME AFTER COVID-19	
9. GENERAL OUTCOMES	SLEEP DIFFICULTY	
9. GENERAL OUTCOMES	SLEEP DIFFICULTY (MILD AND TOLERABLE-MODERATE-SEVERE AND INCAPACITATING)	
9. GENERAL OUTCOMES	SLEEP DISORDERS	
9. GENERAL OUTCOMES	SLEEP DISTURBANCE	
9. GENERAL OUTCOMES	SLEEP DISTURBANCE AND QUALITY	
9. GENERAL OUTCOMES	SLEEP DISTURBANCES	
9. GENERAL OUTCOMES	SLEEP THAT IS RESTLESS OR DISTURBED	
9. GENERAL OUTCOMES	SLEEPING	
9. GENERAL OUTCOMES	SLEEPING DISORDERS	
9. GENERAL OUTCOMES	SOME/LOTS OF PAIN/DISCOMFORT	
9. GENERAL OUTCOMES	SOMNOLENCE	
9. GENERAL OUTCOMES	SPEECH DIFFICULTY	
9. GENERAL OUTCOMES	SPLENOMEGALY	
9. GENERAL OUTCOMES	SYMPTOMS DURING AND AFTER COVID-19 INFECTION	
9. GENERAL OUTCOMES	TEMPERATURE	
9. GENERAL OUTCOMES	THE RISK OF LATE COMPLICATIONS	
9. GENERAL OUTCOMES	TIREDNESS	
9. GENERAL OUTCOMES	TIREDNESS	
9. GENERAL OUTCOMES	TIREDNESS AFTER SLEEP	



9. GENERAL OUTCOMES	TOTAL DIFFICULTIES	
9. GENERAL OUTCOMES	VOICE CHANGES	
9. GENERAL OUTCOMES	WAKE UP AT NIGHT	
9. GENERAL OUTCOMES	WAKE UP TIRED	
9. GENERAL OUTCOMES	WEAKNESS	150
10. HEPATOBILIARY OUTCOMES	ASCITES	
10. HEPATOBILIARY OUTCOMES	HEPATOMEGALY	
10. HEPATOBILIARY OUTCOMES	HEPATOMEGALY AND SPLENOMEGALY	
10. HEPATOBILIARY OUTCOMES	LIVER FUNCTION ABNORMALITY	
10. HEPATOBILIARY OUTCOMES	LIVER/METABOLIC FUNCTION	5
11. IMMUNE SYSTEM OUTCOMES	ANTIBODY DETERMINATIONS	
11. IMMUNE SYSTEM OUTCOMES	CD4+ AND CD8+ T CELL LEVELS IN CENTRAL MEMORY	
11. IMMUNE SYSTEM OUTCOMES	CD4+ AND CD8+ T CELL LEVELS IN EFFECTOR MEMORY	
11. IMMUNE SYSTEM OUTCOMES	COPIES OF SARS-CoV-2	
11. IMMUNE SYSTEM OUTCOMES	DURATION OF FEVER	
11. IMMUNE SYSTEM OUTCOMES	ELEVATED LEVELS OF IL6 AND IL1B IN SERUM	
11. IMMUNE SYSTEM OUTCOMES	FOT INDICES CORRELATION	
11. IMMUNE SYSTEM OUTCOMES	HABIT TO EVALUATE THE ANTIBODY	
11. IMMUNE SYSTEM OUTCOMES	HEMOPHAGOCYTOSIS SYNDROME	
11. IMMUNE SYSTEM OUTCOMES	HIGH LEVEL OF IGM	
11. IMMUNE SYSTEM OUTCOMES	HIGH LEVELS OF IGD-CD27+ MEMORY	
11. IMMUNE SYSTEM OUTCOMES	HIGH LEVELS OF PLASMABLASTS	
11. IMMUNE SYSTEM OUTCOMES	IGA, IGG, IGM, RBD, S1, S2, N-PROTEIN	
11. IMMUNE SYSTEM OUTCOMES	IgG	
11. IMMUNE SYSTEM OUTCOMES	IgM	
11. IMMUNE SYSTEM OUTCOMES	IGM AND IGG LEVEL AND IF THERE IS IMMUNOLOGICAL CHANGES	

11. IMMUNE SYSTEM OUTCOMES	IMMUNE SYSTEM	
11. IMMUNE SYSTEM OUTCOMES	IMMUNOLOGICAL MARKERS	
11. IMMUNE SYSTEM OUTCOMES	IMMUNOLOGICAL PANEL	
11. IMMUNE SYSTEM OUTCOMES	KAWASAKI DISEASE AFTER COVID-19	
11. IMMUNE SYSTEM OUTCOMES	KAWASAKIS DISEASE	
11. IMMUNE SYSTEM OUTCOMES	LEVELS OF ANTIBODIES	
11. IMMUNE SYSTEM OUTCOMES	LOW GRADE FEVER	
11. IMMUNE SYSTEM OUTCOMES	LOW-GRADE FEVER	
11. IMMUNE SYSTEM OUTCOMES	LOWER LEVEL OF IGM+ CD27-CD38DIM B-CELL SUBSETS	
11. IMMUNE SYSTEM OUTCOMES	LOWER LEVEL OF NAÏVE AND UNSWITCHED IGM+ IGD+ B-CELL SUBSETS (CF. TO HEALED CHILDREN)	
11. IMMUNE SYSTEM OUTCOMES	MIS-C AFTER COVID-19	
11. IMMUNE SYSTEM OUTCOMES	MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C)	
11. IMMUNE SYSTEM OUTCOMES	NEUTRALIZING ANTIBODY	
11. IMMUNE SYSTEM OUTCOMES	NEUTRALIZING ANTIBODY OF SARS-CoV-2	
11. IMMUNE SYSTEM OUTCOMES	NON-NEUTRALIZING ANTIBODIES	
11. IMMUNE SYSTEM OUTCOMES	NUCLEOCAPSID ANTIBODY	
11. IMMUNE SYSTEM OUTCOMES	OCCASIONAL FEVER	
11. IMMUNE SYSTEM OUTCOMES	PERSISTENT FEVER	
11. IMMUNE SYSTEM OUTCOMES	PIMS	
11. IMMUNE SYSTEM OUTCOMES	PROBABLE SEPSIS	
11. IMMUNE SYSTEM OUTCOMES	PROLONGED FEVER	
11. IMMUNE SYSTEM OUTCOMES	PROLONGED LOW-GRADE FEVER	
11. IMMUNE SYSTEM OUTCOMES	RECURRENT FEBRILE EPISODES	
11. IMMUNE SYSTEM OUTCOMES	SARS-CoV-2 ANTIBODIES	
11. IMMUNE SYSTEM OUTCOMES	SARS-CoV-2-SPECIFIC CD4 + AND CD8 + T CELLS	
11. IMMUNE SYSTEM OUTCOMES	SARS-CoV-2-SPECIFIC IGG POSITIVITY	

11. IMMUNE SYSTEM OUTCOMES	SEROPOSITIVE PATIENTS	
11. IMMUNE SYSTEM OUTCOMES	SPIKE PROTEIN ANTIBODY	
11. IMMUNE SYSTEM OUTCOMES	SWITCHED IGM IGD-B CELLS	
11. IMMUNE SYSTEM OUTCOMES	VIRUS ANTIBODY	
11. IMMUNE SYSTEM OUTCOMES	VIRUS SPECIFIC NEUTRALIZING ANTIBODIES	
11. IMMUNE SYSTEM OUTCOMES	VIRUS-NEUTRALIZING ANTIBODIES	48
12. INFECTION AND INFESTATION OUTCOMES	CHANGE IN CHILD SARS-CoV-2 VACCINATION STATUS	
12. INFECTION AND INFESTATION OUTCOMES	CULTURE POSITIVE SEPSIS	
12. INFECTION AND INFESTATION OUTCOMES	DURATION OF ANTIBIOTICS	
12. INFECTION AND INFESTATION OUTCOMES	INCIDENCE AND PREVALENCE OF REINFECTION	
12. INFECTION AND INFESTATION OUTCOMES	NO REDETECTABLE POSITIVE	
12. INFECTION AND INFESTATION OUTCOMES	POSITIVE/NEGATIVE	
12. INFECTION AND INFESTATION OUTCOMES	RE-DETECTABLE POSITIVE (RP)	
12. INFECTION AND INFESTATION OUTCOMES	REINFECTION	
12. INFECTION AND INFESTATION OUTCOMES	REINFECTIONS	
12. INFECTION AND INFESTATION OUTCOMES	RNA LEVELS OF ACE2, TMPRSS2 IN ORGANS	
12. INFECTION AND INFESTATION OUTCOMES	SPECIFIC T CELL RESPONSE TO SARS-CoV-2	11
13. INJURY AND POISONING OUTCOMES	BRUISES	

13. INJURY AND POISONING OUTCOMES	BURN	2
14. METABOLISM AND NUTRITION OUTCOMES	ANOREXIA	
14. METABOLISM AND NUTRITION OUTCOMES	ANOREXIA (LOSS OF APPETITE)	
14. METABOLISM AND NUTRITION OUTCOMES	BODY WEIGHT CHANGES	
14. METABOLISM AND NUTRITION OUTCOMES	CACHEXIA	
14. METABOLISM AND NUTRITION OUTCOMES	EATING CHANGES AFTER COVID-19 (LESS/THE SAME/MORE)	
14. METABOLISM AND NUTRITION OUTCOMES	LACK OF APPETITE	
14. METABOLISM AND NUTRITION OUTCOMES	LOSS OF APPETITE	
14. METABOLISM AND NUTRITION OUTCOMES	LOSS OF APPETITE (NO EATING OR OFF THEIR FOOD)	
14. METABOLISM AND NUTRITION OUTCOMES	MEALS SKIP	
14. METABOLISM AND NUTRITION OUTCOMES	NOT FEEDING WELL	
14. METABOLISM AND NUTRITION OUTCOMES	OVEREATING	
14. METABOLISM AND NUTRITION OUTCOMES	POOR APPETITE	
14. METABOLISM AND NUTRITION OUTCOMES	POOR FEEDING/LETHARGY	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT	

14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT AFTER COVID-19	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT AFTER COVID-19 ILLNESS	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT BEFORE COVID-19	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT BEFORE COVID-19 ILLNESS	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT BEFORE/AFTER	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT GAIN/LOSS	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT GAIN/LOSS, EATING DISORDERS	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT LOSS	
14. METABOLISM AND NUTRITION OUTCOMES	WEIGHT LOSS OF >5% OF BODY WEIGHT	23
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	ARTHRALGIA	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	ARTHRITIDES	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	BACK PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	ELBOW PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	JOINT PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	JOINT PAIN OR SWELLING	

15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	JOINT PAINS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	KNEE PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	LESS STRENGTH IN MUSCLES	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	LIMB PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE ACHES	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE AND JOINT PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE SPASMS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE STRENGTH OF LOWER (ILIOPSOAS (HIP FLEXION) LEFT AND RIGHT LIMBS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE STRENGTH OF QUADRICEPS (KNEE EXTENSION) LEFT AND RIGHT LIMBS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE STRENGTH OF THE UPPER (BICEPS (ELBOW FLEXION) LEFT AND RIGHT LIMBS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE STRENGTH OF TIBIALIS ANTERIOR (ANKLE DORSIFLEXION) LEFT AND RIGHT LIMBS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE STRENGTH OF TRICEPS (ELBOW EXTENSION) LEFT AND RIGHT LIMBS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE WEAKNES	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE WEAKNESS	

15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MUSCLE WEAKNESS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MYALGIA	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	MYALGIAS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	NECK/SHOULDER PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	PAINS IN LOWER BACK	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	PERSISTENT MUSCLE PAIN	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	SORENESS OF YOUR MUSCLES	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	STIFFNESS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	STRONG MUSCLE PAINS	
15. MUSCULOSKELETAL AND CONNECTIVE TISSUE OUTCOMES	UNUSUALLY STRONG MUSCLE PAINS	31
16. OUTCOMES RELATING TO NEOPLASMS: BENIGN, MALIGNANT AND UNSPECIFIED (INCLUDING CYSTS AND POLYPS)		
17. NERVOUS SYSTEM OUTCOMES	AGEUSIA	
17. NERVOUS SYSTEM OUTCOMES	ANOSMIA	
17. NERVOUS SYSTEM OUTCOMES	ANOSMIA-AGEUSIA OR PAROSMIA/EUOSMIA	
17. NERVOUS SYSTEM OUTCOMES	ANOSMIA/AGEUSIA	
17. NERVOUS SYSTEM OUTCOMES	AUTONOMIC DYSFUNCTION	
17. NERVOUS SYSTEM OUTCOMES	BALANCE PROBLEMS	

17. NERVOUS SYSTEM OUTCOMES	CEREBRAL HAEMORRHAGE	
17. NERVOUS SYSTEM OUTCOMES	CHANGED STATE OF CONSCIOUSNESS	
17. NERVOUS SYSTEM OUTCOMES	CHANGED TASTE	
17. NERVOUS SYSTEM OUTCOMES	CHRONIC HEADACHE	
17. NERVOUS SYSTEM OUTCOMES	COLLAPSE	
17. NERVOUS SYSTEM OUTCOMES	COMA	
17. NERVOUS SYSTEM OUTCOMES	CONFUSION	
17. NERVOUS SYSTEM OUTCOMES	CONFUSION/BRAIN FOG/TROUBLE FOCUSING ATTENTION	
17. NERVOUS SYSTEM OUTCOMES	CONFUSION/DISORIENTATION/DROWSINESS	
17. NERVOUS SYSTEM OUTCOMES	CONSTANTLY FIDGETING OR SQUIRMING (I AM CONSTANTLY FIDGETING....)	
17. NERVOUS SYSTEM OUTCOMES	COORDINATION ISSUES	
17. NERVOUS SYSTEM OUTCOMES	DECREASED SENSE OF SMELL	
17. NERVOUS SYSTEM OUTCOMES	DECREASED SENSE OF SMELL/TASTE	
17. NERVOUS SYSTEM OUTCOMES	DECREASED SENSE OF TASTE	
17. NERVOUS SYSTEM OUTCOMES	DEVELOPMENTAL DELAY	
17. NERVOUS SYSTEM OUTCOMES	DEVELOPMENTAL REGRESSION	
17. NERVOUS SYSTEM OUTCOMES	DIFFICULTY SWALLOWING	
17. NERVOUS SYSTEM OUTCOMES	DISTURBED SMELL	
17. NERVOUS SYSTEM OUTCOMES	DISTURBED TASTE	
17. NERVOUS SYSTEM OUTCOMES	DIZZINESS	
17. NERVOUS SYSTEM OUTCOMES	DIZZINESS ± SYNCOPE	
17. NERVOUS SYSTEM OUTCOMES	DIZZINESS/ LIGHT HEADEDNESS	
17. NERVOUS SYSTEM OUTCOMES	DROWSINESS	
17. NERVOUS SYSTEM OUTCOMES	DUCHENNE MUSCULAR DYSTROPHY	
17. NERVOUS SYSTEM OUTCOMES	DYSGEUSIA	
17. NERVOUS SYSTEM OUTCOMES	DYSGEUSIA/ANOSMIA	



17. NERVOUS SYSTEM OUTCOMES	DYSLEXIA	
17. NERVOUS SYSTEM OUTCOMES	ENCEPHALITIS	
17. NERVOUS SYSTEM OUTCOMES	FACIAL NERVE PARALYSIS	
17. NERVOUS SYSTEM OUTCOMES	FACIAL PAIN/PRESSURE	
17. NERVOUS SYSTEM OUTCOMES	FAINING/ BLACKOUTS	
17. NERVOUS SYSTEM OUTCOMES	FAININESS	
17. NERVOUS SYSTEM OUTCOMES	FAININESS OR DIZZINESS	
17. NERVOUS SYSTEM OUTCOMES	FEELING OFF-BALANCE OR UNSTEADY	
17. NERVOUS SYSTEM OUTCOMES	FEELING TENSE OR KEYED UP	
17. NERVOUS SYSTEM OUTCOMES	FEELING WEAK IN PARTS OF YOUR BODY	
17. NERVOUS SYSTEM OUTCOMES	GROWTH AND NEURODEVELOPMENT	
17. NERVOUS SYSTEM OUTCOMES	GUILLIAN-BARRÉ SYNDROME	
17. NERVOUS SYSTEM OUTCOMES	HEADACHE, DIZZINESS	
17. NERVOUS SYSTEM OUTCOMES	HEADACHES	
17. NERVOUS SYSTEM OUTCOMES	HEAVY FEELINGS IN YOUR ARMS OR LEGS	
17. NERVOUS SYSTEM OUTCOMES	IMPAIRED BALANCE	
17. NERVOUS SYSTEM OUTCOMES	INCREASED NIGHTMARES OR SLEEPWALKING	
17. NERVOUS SYSTEM OUTCOMES	ISCHAEMIC STROKE OR TIA	
17. NERVOUS SYSTEM OUTCOMES	LOSS OF BALANCE	
17. NERVOUS SYSTEM OUTCOMES	LOSS OF SMELL	
17. NERVOUS SYSTEM OUTCOMES	LOSS OF SMELL/TASTE	
17. NERVOUS SYSTEM OUTCOMES	LOSS OF TASTE	
17. NERVOUS SYSTEM OUTCOMES	LOSS OF TASTE AND/OR SMELL	
17. NERVOUS SYSTEM OUTCOMES	MENINGISMUS	
17. NERVOUS SYSTEM OUTCOMES	MENINGITIS	
17. NERVOUS SYSTEM OUTCOMES	MOTOR PROBLEMS	

17. NERVOUS SYSTEM OUTCOMES	NEURODEVELOPMENTAL OUTCOME	
17. NERVOUS SYSTEM OUTCOMES	NEUROLOGIC SEQUELAE	
17. NERVOUS SYSTEM OUTCOMES	NEUROLOGICAL ABNORMALITIES	
17. NERVOUS SYSTEM OUTCOMES	NEUROLOGICAL MANIFESTATION OF POST-COVID	
17. NERVOUS SYSTEM OUTCOMES	NEUROPATHIES	
17. NERVOUS SYSTEM OUTCOMES	NORMOSMIA	
17. NERVOUS SYSTEM OUTCOMES	NUMBNESS OR TINGLING IN PARTS OF YOUR BODY	
17. NERVOUS SYSTEM OUTCOMES	OFTEN COMPLAINS OF HEADACHES... (I GET A LOT OF HEADACHES...)	
17. NERVOUS SYSTEM OUTCOMES	OLFACTION RECOVERY	
17. NERVOUS SYSTEM OUTCOMES	OTHER COORDINATION DISORDERS/ATAXIA	
17. NERVOUS SYSTEM OUTCOMES	PARAESTHESIA AND ANESTHESIA	
17. NERVOUS SYSTEM OUTCOMES	PARESIS	
17. NERVOUS SYSTEM OUTCOMES	PARESTHESIA	
17. NERVOUS SYSTEM OUTCOMES	PARESTHESIA OF SKIN	
17. NERVOUS SYSTEM OUTCOMES	PATHOLOGICAL REFLEXES	
17. NERVOUS SYSTEM OUTCOMES	PINS AND NEEDLES	
17. NERVOUS SYSTEM OUTCOMES	PROBLEMS WITH BALANCE	
17. NERVOUS SYSTEM OUTCOMES	REDUCED SMELL	
17. NERVOUS SYSTEM OUTCOMES	REDUCED TASTE	
17. NERVOUS SYSTEM OUTCOMES	SEIZURE	
17. NERVOUS SYSTEM OUTCOMES	SEIZURES	
17. NERVOUS SYSTEM OUTCOMES	SEIZURES/FITS	
17. NERVOUS SYSTEM OUTCOMES	SENSATION AND PERCEPTION	
17. NERVOUS SYSTEM OUTCOMES	SENSATION AND PERCEPTION DISORDER	
17. NERVOUS SYSTEM OUTCOMES	SENSORY DISTURBANCES	
17. NERVOUS SYSTEM OUTCOMES	SEVERE RECURRENT HEADACHES	

17. NERVOUS SYSTEM OUTCOMES	SHAKING	
17. NERVOUS SYSTEM OUTCOMES	SLIPS OF THE TONGUE WHEN SPEAKING	
17. NERVOUS SYSTEM OUTCOMES	SLURRED SPEECH	
17. NERVOUS SYSTEM OUTCOMES	SOPOR	
17. NERVOUS SYSTEM OUTCOMES	SOPOR/COMA	
17. NERVOUS SYSTEM OUTCOMES	STROKE	
17. NERVOUS SYSTEM OUTCOMES	SYNCOPE	
17. NERVOUS SYSTEM OUTCOMES	TETANY	
17. NERVOUS SYSTEM OUTCOMES	TIC EXACERBATION	
17. NERVOUS SYSTEM OUTCOMES	TINGLING	
17. NERVOUS SYSTEM OUTCOMES	TINGLING FEELING/ 'PINS AND NEEDLES'	
17. NERVOUS SYSTEM OUTCOMES	TINGLING/NUMBNESS IN ARMS/LEGS	
17. NERVOUS SYSTEM OUTCOMES	TREMBLING	
17. NERVOUS SYSTEM OUTCOMES	TREMOR	
17. NERVOUS SYSTEM OUTCOMES	TREMOR/SHAKINESS	
17. NERVOUS SYSTEM OUTCOMES	TREMULOUSNESS	
17. NERVOUS SYSTEM OUTCOMES	TROUBLE FALLING ASLEEP	
17. NERVOUS SYSTEM OUTCOMES	TWITCHING OF FINGERS/TOES	
17. NERVOUS SYSTEM OUTCOMES	VERTIGO	103
18. PREGNANCY, PUERPERIUM AND PERINATAL OUTCOMES		
19. RENAL AND URINARY OUTCOMES	ACUTE KIDNEY INJURY	
19. RENAL AND URINARY OUTCOMES	ANURIA	
19. RENAL AND URINARY OUTCOMES	ANURIA/OLIGURIA	
19. RENAL AND URINARY OUTCOMES	DYSURIA	
19. RENAL AND URINARY OUTCOMES	KIDNEY FAILURE	
19. RENAL AND URINARY OUTCOMES	KIDNEY FUNCTION	

19. RENAL AND URINARY OUTCOMES	KIDNEY PROBLEMS AFTER COVID-19	
19. RENAL AND URINARY OUTCOMES	KIDNEY/METABOLIC FUNCTION	
19. RENAL AND URINARY OUTCOMES	MICROHAEMATURIA	
19. RENAL AND URINARY OUTCOMES	OLIGURIA	
19. RENAL AND URINARY OUTCOMES	OTHER SYMPTOMS OF THE URINARY SYSTEM	
19. RENAL AND URINARY OUTCOMES	POLYURIA	
19. RENAL AND URINARY OUTCOMES	PROBLEMS WITH URINATION	
19. RENAL AND URINARY OUTCOMES	RENAL FAILURE	
19. RENAL AND URINARY OUTCOMES	URETHRAL DISCHARGE	
19. RENAL AND URINARY OUTCOMES	URINARY INCONTINENCE	
19. RENAL AND URINARY OUTCOMES	URINARY RETENTION	
19. RENAL AND URINARY OUTCOMES	URINATION PROBLEMS	
19. RENAL AND URINARY OUTCOMES	URINE	19
20. REPRODUCTIVE SYSTEM AND BREAST OUTCOMES	CHANGE IN MENSTRUATION	
20. REPRODUCTIVE SYSTEM AND BREAST OUTCOMES	CHANGES IN MENSTRUATION	
20. REPRODUCTIVE SYSTEM AND BREAST OUTCOMES	DYSMENORRHEA	
20. REPRODUCTIVE SYSTEM AND BREAST OUTCOMES	MENSTRUAL DISTURBANCES	
20. REPRODUCTIVE SYSTEM AND BREAST OUTCOMES	PATHOLOGICAL FINDINGS FROM MALE GENITAL TRACT	5
21. PSYCHIATRIC OUTCOMES	ABILITY TO MAKE UP OWN MIND ABOUT THINGS	
21. PSYCHIATRIC OUTCOMES	ADAPTIVE BEHAVIOR SCORE	
21. PSYCHIATRIC OUTCOMES	ADJUSTMENT DISORDER	
21. PSYCHIATRIC OUTCOMES	ANXIETY	
21. PSYCHIATRIC OUTCOMES	ANXIETY DISORDER	

21. PSYCHIATRIC OUTCOMES	ANXIETY OR DEPRESSION	
21. PSYCHIATRIC OUTCOMES	ANXIETY/DEPRESSION	
21. PSYCHIATRIC OUTCOMES	APATHY, SAD FEELING	
21. PSYCHIATRIC OUTCOMES	AWAKENING IN THE EARLY MORNING	
21. PSYCHIATRIC OUTCOMES	BEHAVIORAL SYMPTOMS	
21. PSYCHIATRIC OUTCOMES	BEHAVIOUR	
21. PSYCHIATRIC OUTCOMES	BLAMING YOURSELF FOR THINGS	
21. PSYCHIATRIC OUTCOMES	CONCENTRATION IMPAIRMENT	
21. PSYCHIATRIC OUTCOMES	CONSTANTLY CRYING	
21. PSYCHIATRIC OUTCOMES	CRYING EASILY	
21. PSYCHIATRIC OUTCOMES	DEALING WITH PROBLEMS WELL	
21. PSYCHIATRIC OUTCOMES	DEPRESSED MOOD	
21. PSYCHIATRIC OUTCOMES	DEPRESSION	
21. PSYCHIATRIC OUTCOMES	DEPRESSIVE SYMPTOMS	
21. PSYCHIATRIC OUTCOMES	DIFFICULTY MAKING DECISIONS	
21. PSYCHIATRIC OUTCOMES	EASILY DISTRACTED, CONCENTRATION WANDERS (I AM EASILY DISTRACTED)	
21. PSYCHIATRIC OUTCOMES	EMBARRASSED	
21. PSYCHIATRIC OUTCOMES	EMOTIONAL AND BEHAVIORAL DISORDER	
21. PSYCHIATRIC OUTCOMES	EMOTIONAL AND MENTAL HEALTH	
21. PSYCHIATRIC OUTCOMES	EMOTIONALITY	
21. PSYCHIATRIC OUTCOMES	EMOTIONS	
21. PSYCHIATRIC OUTCOMES	EUPHORIA	
21. PSYCHIATRIC OUTCOMES	EXCESSIVE CRYING	
21. PSYCHIATRIC OUTCOMES	FEELING AFRAID IN OPEN SPACES OR ON THE STREETS	
21. PSYCHIATRIC OUTCOMES	FEELING AFRAID TO GO OUT OF YOUR HOUSE ALONE	
21. PSYCHIATRIC OUTCOMES	FEELING AFRAID TO TRAVEL ON BUSES, SUBWAYS, TRAINS	

21. PSYCHIATRIC OUTCOMES	FEELING AFRAID YOU WILL FAINT IN PUBLIC	
21. PSYCHIATRIC OUTCOMES	FEELING BLOCKED IN GETTING THINGS DONE	
21. PSYCHIATRIC OUTCOMES	FEELING BLUE	
21. PSYCHIATRIC OUTCOMES	FEELING CRITICAL OF OTHERS	
21. PSYCHIATRIC OUTCOMES	FEELING EASILY ANNOYED OR IRRITATED	
21. PSYCHIATRIC OUTCOMES	FEELING EVERYTHING IS AN EFFORT	
21. PSYCHIATRIC OUTCOMES	FEELING FEARFUL	
21. PSYCHIATRIC OUTCOMES	FEELING HOPELESS ABOUT THE FUTURE	
21. PSYCHIATRIC OUTCOMES	FEELING INFERIOR TO OTHERS	
21. PSYCHIATRIC OUTCOMES	FEELING LONELY	
21. PSYCHIATRIC OUTCOMES	FEELING LONELY EVEN WHEN YOU ARE WITH PEOPLE	
21. PSYCHIATRIC OUTCOMES	FEELING LOW IN ENERGY OR SLOWED DOWN	
21. PSYCHIATRIC OUTCOMES	FEELING NERVOUS WHEN YOU ARE LEFT ALONE	
21. PSYCHIATRIC OUTCOMES	FEELING NO INTEREST IN THINGS	
21. PSYCHIATRIC OUTCOMES	FEELING OF BEING TRAPPED OR CAUGHT	
21. PSYCHIATRIC OUTCOMES	FEELING OTHERS ARE TO BLAME FOR MOST OF YOUR TROUBLES	
21. PSYCHIATRIC OUTCOMES	FEELING OTHERS DO NOT UNDERSTAND YOU OR ARE UNSYMPATHETIC	
21. PSYCHIATRIC OUTCOMES	FEELING PUSHED TO GET THINGS DONE	
21. PSYCHIATRIC OUTCOMES	FEELING SHY OR UNEASY WITH THE OPPOSITE SEX	
21. PSYCHIATRIC OUTCOMES	FEELING SO RESTLESS YOU COULDN'T SIT STILL	
21. PSYCHIATRIC OUTCOMES	FEELING THAT FAMILIAR THINGS ARE STRANGE OR UNREAL	
21. PSYCHIATRIC OUTCOMES	FEELING THAT MOST PEOPLE CANNOT BE TRUSTED	
21. PSYCHIATRIC OUTCOMES	FEELING THAT PEOPLE ARE UNFRIENDLY OR DISLIKE YOU	
21. PSYCHIATRIC OUTCOMES	FEELING THAT PEOPLE WILL TAKE ADVANTAGE OF YOU IF YOU LET THEM	
21. PSYCHIATRIC OUTCOMES	FEELING THAT YOU ARE WATCHED OR TALKED ABOUT BY OTHERS	
21. PSYCHIATRIC OUTCOMES	FEELING UNCOMFORTABLE ABOUT EATING OR DRINKING IN PUBLIC	

21. PSYCHIATRIC OUTCOMES	FEELING UNEASY IN CROWDS, SUCH AS SHOPPING OR AT A MOVIE	
21. PSYCHIATRIC OUTCOMES	FEELING UNEASY WHEN PEOPLE ARE WATCHING OR TALKING ABOUT YOU	
21. PSYCHIATRIC OUTCOMES	FEELING USEFUL	
21. PSYCHIATRIC OUTCOMES	FEELING VERY SELF-CONSCIOUS WITH OTHERS	
21. PSYCHIATRIC OUTCOMES	FEELINGS OF GUILT	
21. PSYCHIATRIC OUTCOMES	FEELINGS OF WORTHLESSNESS	
21. PSYCHIATRIC OUTCOMES	FLOPPY OR DIFFICULTY ROUSING	
21. PSYCHIATRIC OUTCOMES	FRUSTRATED/RESTLESS/IRRITABLE	
21. PSYCHIATRIC OUTCOMES	GETTING INTO FREQUENT ARGUMENTS	
21. PSYCHIATRIC OUTCOMES	HALLUCINATIONS	
21. PSYCHIATRIC OUTCOMES	HAVING DIFFICULTY SLEEPING AT NIGHT/GETTING TO SLEEP	
21. PSYCHIATRIC OUTCOMES	HAVING IDEAS OR BELIEFS THAT OTHERS DO NOT SHARE	
21. PSYCHIATRIC OUTCOMES	HAVING THOUGHTS ABOUT SEX THAT BOTHER YOU A LOT	
21. PSYCHIATRIC OUTCOMES	HAVING THOUGHTS THAT ARE NOT YOUR OWN	
21. PSYCHIATRIC OUTCOMES	HAVING TO AVOID CERTAIN THINGS, PLACES, OR ACTIVITIES BECAUSE THEY FRIGHTEN YOU	
21. PSYCHIATRIC OUTCOMES	HAVING TO CHECK AND DOUBLE-CHECK WHAT YOU DO	
21. PSYCHIATRIC OUTCOMES	HAVING TO DO THINGS VERY SLOWLY TO INSURE CORRECTNESS	
21. PSYCHIATRIC OUTCOMES	HAVING TO REPEAT THE SAME ACTIONS SUCH AS TOUCHING, COUNTING, WASHING	
21. PSYCHIATRIC OUTCOMES	HAVING TO SLEEP UPRIGHT	
21. PSYCHIATRIC OUTCOMES	HAVING URGES TO BEAT, INJURE, OR HARM SOMEONE	
21. PSYCHIATRIC OUTCOMES	HAVING URGES TO BREAK OR SMASH THINGS	
21. PSYCHIATRIC OUTCOMES	HEARING VOICES THAT OTHER PEOPLE DO NOT HEAR	
21. PSYCHIATRIC OUTCOMES	IDEAS OF PERSECUTION	
21. PSYCHIATRIC OUTCOMES	INCREASED AGGRESSIVENESS	
21. PSYCHIATRIC OUTCOMES	INCREASED ANXIETY	
21. PSYCHIATRIC OUTCOMES	INCREASED MOOD SWINGS	

21. PSYCHIATRIC OUTCOMES	IRRITABILITY	
21. PSYCHIATRIC OUTCOMES	IRRITABLE	
21. PSYCHIATRIC OUTCOMES	LETHARGY	
21. PSYCHIATRIC OUTCOMES	LONELINESS	
21. PSYCHIATRIC OUTCOMES	LOSS OF SEXUAL INTEREST OR PLEASURE	
21. PSYCHIATRIC OUTCOMES	MANY FEARS, EASILY SCARED (I HAVE MANY FEARS)	
21. PSYCHIATRIC OUTCOMES	MANY WORRIES (I WORRY A LOT)	
21. PSYCHIATRIC OUTCOMES	MOOD AND BEHAVIOUR CHANGES	
21. PSYCHIATRIC OUTCOMES	MOOD CHANGES	
21. PSYCHIATRIC OUTCOMES	MOOD DISORDER	
21. PSYCHIATRIC OUTCOMES	MOOD SWINGS	
21. PSYCHIATRIC OUTCOMES	NERVOUS OR CLINGY IN NEW SITUATIONS (I AM NERVOUS IN NEW SITUATIONS)	
21. PSYCHIATRIC OUTCOMES	NERVOUSNESS OR SHAKINESS INSIDE	
21. PSYCHIATRIC OUTCOMES	NEURASTHENIA	
21. PSYCHIATRIC OUTCOMES	NEVER FEELING CLOSE TO ANOTHER PERSON	
21. PSYCHIATRIC OUTCOMES	NUMBER OF PSYCHOLOGIC CHANGES	
21. PSYCHIATRIC OUTCOMES	OBSESSIVE-COMPULSIVE SYMPTOMS	
21. PSYCHIATRIC OUTCOMES	OBSESSIVE-COMPULSIVE DISORDER	
21. PSYCHIATRIC OUTCOMES	OFTEN UNHAPPY, DOWNHEARTED (I AM OFTEN UNHAPPY)	
21. PSYCHIATRIC OUTCOMES	OTHER PEOPLE BEING AWARE OF YOUR PRIVATE THOUGHTS	
21. PSYCHIATRIC OUTCOMES	OTHERS NOT GIVING YOU PROPER CREDIT FOR YOUR ACHIEVEMENTS	
21. PSYCHIATRIC OUTCOMES	PERSONALITY	
21. PSYCHIATRIC OUTCOMES	PROBLEMS STARTING THINGS	
21. PSYCHIATRIC OUTCOMES	PSYCHOLOGIC STATUS	
21. PSYCHIATRIC OUTCOMES	PSYCHOLOGICAL/PSYCHIATRIC SYMPTOMS	
21. PSYCHIATRIC OUTCOMES	PSYCHOSIS	



21. PSYCHIATRIC OUTCOMES	RESTLESS, OVERACTIVE (I AM RESTLESS)	
21. PSYCHIATRIC OUTCOMES	SAD	
21. PSYCHIATRIC OUTCOMES	SADNESS	
21. PSYCHIATRIC OUTCOMES	SEES TASKS THROUGH TO THE END (I FINISH THE WORK I AM DOING)	
21. PSYCHIATRIC OUTCOMES	SHOUTING OR THROWING THINGS	
21. PSYCHIATRIC OUTCOMES	SOMATIZATION DISORDER	
21. PSYCHIATRIC OUTCOMES	SPELLS OF TERROR OR PANIC	
21. PSYCHIATRIC OUTCOMES	STEALS FROM HOME, SCHOOL OR ELSEWHERE (I TAKE THINGS THAT ARE NOT MINE)	
21. PSYCHIATRIC OUTCOMES	SUDDENLY SCARED FOR NO REASON	
21. PSYCHIATRIC OUTCOMES	SUICIDAL IDEATION	
21. PSYCHIATRIC OUTCOMES	TEMPER OUTBURSTS THAT YOU COULD NOT CONTROL	
21. PSYCHIATRIC OUTCOMES	TEMPER TANTRUMS/HOT TEMPER (GET VERY ANGRY)	
21. PSYCHIATRIC OUTCOMES	THE IDEA THAT SOMEONE ELSE CAN CONTROL YOUR THOUGHTS	
21. PSYCHIATRIC OUTCOMES	THE IDEA THAT SOMETHING IS WRONG WITH YOUR MIND	
21. PSYCHIATRIC OUTCOMES	THE IDEA THAT SOMETHING SERIOUS IS WRONG WITH YOUR BODY	
21. PSYCHIATRIC OUTCOMES	THE IDEA THAT YOU SHOULD BE PUNISHED FOR YOUR SINS	
21. PSYCHIATRIC OUTCOMES	THINKS THINGS OUT BEFORE ACTING (I THINK BEFORE I DO THINGS)	
21. PSYCHIATRIC OUTCOMES	THOUGHTS OF DEATH OR DYING	
21. PSYCHIATRIC OUTCOMES	THOUGHTS OF ENDING YOUR LIFE	
21. PSYCHIATRIC OUTCOMES	TROUBLE GETTING YOUR BREATH	
21. PSYCHIATRIC OUTCOMES	UNWANTED THOUGHTS, WORDS/IDEAS THAT WON'T LEAVE YOUR MIND	
21. PSYCHIATRIC OUTCOMES	UPSET OR DISTRESS ABOUT CURRENT SYMPTOMS	
21. PSYCHIATRIC OUTCOMES	WORRIED ABOUT SLOPPINESS OR CARELESSNESS	
21. PSYCHIATRIC OUTCOMES	WORRYING TOO MUCH ABOUT THINGS	
21. PSYCHIATRIC OUTCOMES	YOUR FEELINGS BEING EASILY HURT	134
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL 6MWT (6 - MINUTE WALK TEST)	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL AUSCULTATORY FINDINGS: DECREASED BREATH SOUNDS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL AUSCULTATORY FINDINGS: INTERMITTENT WHEEZING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL CHEST RADIOGRAPH	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL LUNG FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL PULMONARY FUNCTION TESTS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL RESPIRATORY FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL SPIROMETRY	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ABNORMAL TLCO - LUNG DIFFUSING CAPACITY FOR CARBON MONOXIDE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ACUTE RESPIRATORY DISTRESS SYNDROME	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ACUTE UPPER RESPIRATORY TRACT INFECTION (AURI)	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	BREATHLESSNESS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	BRONCHIAL ASTHMA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	BRONCHIOLITIS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	BRONCHO-RESPONSIVENESS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHANGES IN LUNG VENTILATION	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHANGES IN OTHER LUNG FUNCTIONS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHARACTERISTICS OF RESISTANCE AND REACTANCE OF LUNG AIRWAYS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHEST PAIN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHEST PAIN/TIGHTNESS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHEST RADIOGRAPH CHANGES	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHEST TIGHTNESS/PAIN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CHRONIC COUGH	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	COMBINED DEFECTS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CONGESTED NOSE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CONGESTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CONSOLIDATION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CORRELATION OF THE SEVERITY OF THE RESPIRATORY INVOLVEMENT DURING THE ACUTE INFECTION WITH THE LONG TERM RESPIRATORY STATUS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	COUGH	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	COUGH WITH EXPECTORATION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	COUGH/DYSPNEA/CHEST TIGHTNESS	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	COUGHING WHEN LYING DOWN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	CT ABNORMALITIES	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DAMAGE TO THE LUNGS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DIFFICULTIES BREATHING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DIFFICULTY BREATHING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DIFFICULTY BREATHING /CHEST TIGHTNESS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DRY COUGH	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DURATION OF OXYGEN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DYSPNEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	DYSPNEA AT REST	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	EARLY EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON LUNG FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	EARLY EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON RESPIRATORY SYMPTOMS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ELEVATED RV/TLC ABOVE 30%	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	EMPHYSEMA/PULMONARY BULLA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ENHANCED LUNG MARKING	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	EXCESS SPUTUM	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	EXERTIONAL DYSPNEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	EXHALED BREATH PROFILES	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	EXPECTORATION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	FCV	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	FEF 25-75%	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	FEV1	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	FEV1/FVC	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	FITS OF COUGHING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	GROUND-GLASS OPACITY	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	HOARSE VOICE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	HOARSENESS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	HYALINE MEMBRANE DISEASE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	HYPOXEMIA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	IMPACT OF DYSPNEA SYMPTOMS ON SPECIFIC ACTIVITIES	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	IMPAIRED PULMONARY DIFFUSION FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	INFLAMMATION ABSORPTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	INTERSTITIAL B-LINES PATTERN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	LATE EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON LUNG FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	LATE EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON RESPIRATORY SYMPTOMS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	LONG TERM SYMPTOMS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	LUNG CAPACITY	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	LUNG FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	LUNG LESIONS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	LUNG TISSUE REPAIR	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MEAN FVL CORRELATION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MECHANICAL VENTILATION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MECONIUM ASPIRATION SYNDROME	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MILD PNEUMONIA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MILD SHORTNESS OF BREATH	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MILD-TO-MODERATE OBSTRUCTIVE DISEASE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MODERATE OBSTRUCTIVE DISEASE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MORPHOLOGICAL CHANGES IN THE LUNG	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	MORPHOLOGICAL CHANGES OF LUNG PARENCHYMA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NASAL BLOCKAGE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NASAL CONGESTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NASAL CONGESTION / RHINORRHEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NASAL CONGESTION/ RHINORRHEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NASAL CONGESTION/ RHINORRHOEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NASAL DISCHARGE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NEED TO BLOW NOSE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NO OBVIOUS ABNORMALITY	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NODULAR SHADOWING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NON-SPECIFIC INTERSTITIAL PNEUMONIA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NORMAL/ABNORMAL	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NORMALIZATION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	NOSE SYMPTOMS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	OBSTRUCTIVE OR RESTRICTIVE DEFECT	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	OBSTRUCTIVE SLEEP APNEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	OBSTRUCTIVE VENTILATORY DEFECTS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	ONGOING SUPPLEMENTAL OXYGEN REQUIREMENT	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	OTHER PULMONARY ABNORMALITIES	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PAIN ON BREATHING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PAIN WHEN BREATHING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PATHOLOGICAL LUNG FINDINGS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PATTERNS OF PULMONARY MICROBIOME	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PERFUSION DEFECTED PERCENTAGE (QDP)	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PERFUSION DEFECTS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PERINATAL ASPHYXIA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PERSISTENT COUGH	



22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PERSISTENT DYSPNEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PLEURAL EFFUSION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PLEURAL INCRASSATION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PLEURAL PAIN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PNEUMONIA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	POST-INFLAMMATION PULMONARY FIBROSIS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	POST-NASAL DISCHARGE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	POTENTIAL PULMONARY SEQUELAE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PULMONARY ABNORMALITIES	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PULMONARY FIBROSIS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PULMONARY FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	PULMONARY FUNCTION CHANGES	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	QDP EXCLUSIVE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	QDP TOTAL	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RADIOLOGIC CHANGES	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESISTANCE R <sub>5</sub> , R <sub>20</sub> , R <sub>5</sub> -R <sub>20</sub> AND REACTANCE X <sub>5</sub> , X <sub>20</sub> , X INSPIRATORY-X EXPIRATORY	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY DISTRESS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY FAILURE AFTER COVID-19	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY FUNCTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY FUNCTION RECOVERY	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY INSUFFECIENCY	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY PROBLEMS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY SEQUELAE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY SEQUELAE OF COVID 19 INFECTION IN CHILDREN, BY CLINICAL EXAMINATION AND LABORATORY INVESTIGATIONS DURING 1 YEAR FOLLOW UP PERIOD	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY SUPPORT	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESPIRATORY SYMPTOMS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESTRICTIVE LUNG DISEASE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RESTRICTIVE/OBSTRUCTIVE LUNG DISEASE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RHINITIS	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RHINORRHOEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RISK FACTORS FOR PULMONARY SEQUELAE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	RUNNY NOSE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SEVERE ACUTE RESPIRATORY SYNDROME	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SHORTNESS OF BREADTH	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SHORTNESS OF BREATH	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SHORTNESS OF BREATH (AT REST)	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SHORTNESS OF BREATH (WITH PHYSICAL ACTIVITIES)	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SHORTNESS OF BREATH WITH NOISY BREATHING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SNEEZING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SORE THROAT	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SPO <sub>2</sub>	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SPO <sub>2</sub> EQUAL AND MORE THAN 92	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SPO <sub>2</sub> LESS THAN 92	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	STUFFY NOSE	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	STUFFY RUNNING NOSE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SUBPLEURAL MULTIPLE CONSOLIDATIONS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	SWOLLEN GLANDS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	TACHYPNEA	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	THICK NASAL DISCHARGE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	THORACIC PAIN COMPLAINTS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	THROAT PAIN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	THROAT SYMPTOMS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	THROAT/CHEST PAIN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	TO CORRELATE FOT INDICES	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	TRANSIENT TACHYPNEA OF NEWBORN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	TROUBLE BREATHING	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	UNUSUAL CHEST PAIN	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	UNUSUALLY HOARSE VOICE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VARYING DEGREES OF USUAL INTERSTITIAL PNEUMONIA	

22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VDP EXCLUSIVE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VDP FVL	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VDP FVL EXCLUSIVE	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VDP TOTAL	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VENTILATION AND PERFUSION OF THE LUNG	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VENTILATION DEFECTED PERCENTAGE (VDP)	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VENTILATION DEFECTS	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VENTILATION/PERFUSION MATCH (VQM DEFECT)	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VENTILATION/PERFUSION MISMATCH (VQM DEFECT)	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VIRAL UPPER RESPIRATORY INFECTION	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VQM DEFECT	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VQM DEFECT, FVL	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VQM NON-DEFECT	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	VQM NON-DEFECT, FVL	
22. RESPIRATORY, THORACIC AND MEDIASTINAL OUTCOMES	WHEEZING	180

23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	BLISTERS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	CORRELATION BETWEEN CUTANEOUS MANIFESTATIONS IN RECOVERED PATIENT OF COVID 19 THERAPEUTIC REGIME USED DURING TREATMENT PERIOD	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	CORRELATION BETWEEN CUTANEOUS MANIFESTATIONS IN RECOVERED PATIENT OF COVID 19 WITH DISEASE SEVERITY	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	CORRELATIONS BETWEEN DEMOGRAPHIC PARAMETER AND SKIN MANIFESTATIONS IN RECOVERED PATIENT OF COVID-19	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	COVID TOE	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	CUTANEOUS RASH	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	DERMATITIS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	DERMATOLOGICAL CHANGES	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	DERMATOLOGICAL SYMPTOMS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	DRY SKIN	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	EDEMA	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	HAIR	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	HAIR LOSS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	HIVES	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	HYPERHIDROSIS	

23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	ITCHING SKIN	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	ITCHY SKIN	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	LUMPS OR RASHES (PURPLE/PINK) ON TOES	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	MOTTLED FEET	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	PLANTAR WART	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	PROBLEMS WITH TEETH OR GUMS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	PSORIASIS FLARE	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	RAISED WELTS ON SKIN OR SWELLING	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	RAISED, RED, ITCHY WELTS ON THE SKIN/SUDDEN SWELLING OF THE FACE OR LIPS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	RASH	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	RASHES	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	RED OR PURPLE SORES OR BLISTERS ON FEET	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	RED WELTS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	RED/PURPLE SORES/BLISTERS ON FEET, INCLUDING TOES	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	REDNESS SKIN	

23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SKIN IRRITATION/LESIONS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SKIN LESIONS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SKIN RASH	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SKIN RASH - IF YES, TICK ALL BODY AREAS THAT APPLY: FACE, TRUNK (STOMACH OR BACK), ARMS, LEGS, BUTTOCKS, TOES, FINGERS, ACCOMPANIED BY ITCH	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SKIN RASHES (FACE, TRUNK, ARMS, LEGS, BUTTOCKS, TOES, FINGERS, ACCOMPANIED BY ITCH)	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SUBCUTANEOUS NODULES	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SWEATINESS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SWELLING	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SWELLING OF BODY	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	SWOLLEN TOES AND/OR FINGERS	
23. SKIN AND SUBCUTANEOUS TISSUE OUTCOMES	URTICARIA	41
24. VASCULAR OUTCOMES	BLEEDING	
24. VASCULAR OUTCOMES	BLEEDING (IF YES, SPECIFY BLEEDING SITE)	
24. VASCULAR OUTCOMES	EPISTAXIS	
24. VASCULAR OUTCOMES	GANGRENE	
24. VASCULAR OUTCOMES	HEMORRHAGE	
24. VASCULAR OUTCOMES	PERIPHERAL VASCULAR DISEASE	
24. VASCULAR OUTCOMES	PULMONARY EMBOLISM	



24. VASCULAR OUTCOMES	PULMONARY EMBOLISM AFTER COVID-19	
24. VASCULAR OUTCOMES	SINUS VEIN THROMBOSIS	
24. VASCULAR OUTCOMES	THROMBOSIS	
24. VASCULAR OUTCOMES	VASCULITIS	
24. VASCULAR OUTCOMES	VASOACTIVE AGENTS USE	
24. VASCULAR OUTCOMES	VASOMOTOR COMPLAINTS	
24. VASCULAR OUTCOMES	VENOUS THROMBOEMBOLISM	14
25. PHYSICAL FUNCTIONING	CANNOT FULLY MOVE OR CONTROL MOVEMENT	
25. PHYSICAL FUNCTIONING	DECREASED ACTIVITY LEVEL	
25. PHYSICAL FUNCTIONING	DECREASED PHYSICAL STRENGTH	
25. PHYSICAL FUNCTIONING	EARLY EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON EXERCISE CAPACITY	
25. PHYSICAL FUNCTIONING	EXERCISE CAPACITY	
25. PHYSICAL FUNCTIONING	EXERCISE INTOLERANCE	
25. PHYSICAL FUNCTIONING	EXERCISE TOLERANCE	
25. PHYSICAL FUNCTIONING	FEELING EXHAUSTED AFTER WALKING	
25. PHYSICAL FUNCTIONING	FUNCTIONAL SECONDARY OUTCOMES	
25. PHYSICAL FUNCTIONING	IMPAIRMENT IN DAILY ACTIVITIES	
25. PHYSICAL FUNCTIONING	LATE EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON EXERCISE CAPACITY	
25. PHYSICAL FUNCTIONING	LOWER LIMB MUSCLE ENDURANCE	
25. PHYSICAL FUNCTIONING	MILD LIMITATIONS IN DAILY FUNCTIONING	
25. PHYSICAL FUNCTIONING	MOVEMENT DISORDERS	
25. PHYSICAL FUNCTIONING	MUSCLE STRENGTH	
25. PHYSICAL FUNCTIONING	NO LIMITATIONS IN DAILY FUNCTIONING	
25. PHYSICAL FUNCTIONING	NUMBER OF FUNCTIONAL LIMITATIONS	
25. PHYSICAL FUNCTIONING	OVERALL PHYSICAL FUNCTION RECOVERY	
25. PHYSICAL FUNCTIONING	PHYSICAL ACTIVITY	

25. PHYSICAL FUNCTIONING	PHYSICAL FUNCTION	
25. PHYSICAL FUNCTIONING	PHYSICAL SCORE	
25. PHYSICAL FUNCTIONING	PHYSICAL STRENGTH	
25. PHYSICAL FUNCTIONING	PHYSICAL SYMPTOMS	
25. PHYSICAL FUNCTIONING	POST-EXCERCITIONAL MALAISE	
25. PHYSICAL FUNCTIONING	REDUCED PHYSICAL PERFORMANCE	
25. PHYSICAL FUNCTIONING	SEVERE LIMITATIONS IN DAILY FUNCTIONING	
25. PHYSICAL FUNCTIONING	SHORTNESS OF BREATH AFTER ACTIVITY	
25. PHYSICAL FUNCTIONING	SHORTNESS OF BREATH AT REST	
25. PHYSICAL FUNCTIONING	SOME/LOTS OF MOBILITY PROBLEMS	
25. PHYSICAL FUNCTIONING	SOME/LOTS OF PROBLEMS WITH USUAL ACTIVITIES	
25. PHYSICAL FUNCTIONING	SOME/LOTS OF SELF-CARE PROBLEMS	
25. PHYSICAL FUNCTIONING	WALKING INTOLERANCE	32
26. SOCIAL FUNCTIONING	CONSIDERATE OF OTHER PEOPLE'S FEELINGS (I TRY TO BE NICE TO OTHER PEOPLE)	
26. SOCIAL FUNCTIONING	FEELING CLOSE TO OTHER PEOPLE	
26. SOCIAL FUNCTIONING	GENERALLY LIKED BY OTHER CHILDREN (OTHER PEOPLE MY AGE GENERALLY LIKE ME)	
26. SOCIAL FUNCTIONING	GENERALLY OBEDIENT... (I USUALLY DO AS I AM TOLD)	
26. SOCIAL FUNCTIONING	GETS ON BETTER WITH ADULTS THAN WITH OTHER CHILDREN (I GET ON BETTER WITH ADULTS THAN WITH PEOPLE MY AGE)	
26. SOCIAL FUNCTIONING	HAS AT LEAST ONE GOOD FRIEND (I HAVE ONE GOOD FRIEND OR MORE)	
26. SOCIAL FUNCTIONING	HELPFUL IF SOMEONE IS HURT (I AM HELPFUL IS SOMEONE IS HURT...)	
26. SOCIAL FUNCTIONING	KIND TO YOUNGER CHILDREN (I AM KIND TO YOUNGER CHILDREN)	
26. SOCIAL FUNCTIONING	OFTEN FIGHTS WITH OTHER CHILDREN... (I FIGHT A LOT)	
26. SOCIAL FUNCTIONING	OFTEN LIES OR CHEATS (I AM OFTEN ACCUSED OF LYING OR CHEATING)	
26. SOCIAL FUNCTIONING	OFTEN VOLUNTEERS TO HELP OTHERS (I OFTEN VOLUNTEER TO HELP OTHERS)	

26. SOCIAL FUNCTIONING	PICKED ON OR BULLIED BY OTHER CHILDREN (OTHER CHILDREN OR YOUNG PEOPLE PICK ON ME)	
26. SOCIAL FUNCTIONING	RATHER SOLITARY, TENDS TO PLAY ALONE (I AM USUALLY ON MY OWN)	
26. SOCIAL FUNCTIONING	RELATIONSHIPS	
26. SOCIAL FUNCTIONING	SHARES READILY WITH OTHER CHILDREN (I USUALLY SHARE WITH OTHERS)	
26. SOCIAL FUNCTIONING	SPENDING TIME WITH FRIENDS IN PERSON	
26. SOCIAL FUNCTIONING	SPENDING TIME WITH FRIENDS REMOTELY	17
27. ROLE FUNCTIONING	ABSENCE AT SCHOOL/KINDERGARTEN AFTER RECOVERING FROM COVID-19 BECAUSE OF THE ABOVE SYMPTOMS?	
27. ROLE FUNCTIONING	ATTENDING SCHOOL/NURSERY	
27. ROLE FUNCTIONING	REDUCED PRODUCTIVITY	3
28. EMOTIONAL FUNCTIONING/WELLBEING	A BIT/VERY WORRIED, SAD/UNHAPPY	
28. EMOTIONAL FUNCTIONING/WELLBEING	EVERYDAY WAS FULL OF THINGS THAT INTEREST THE CHILD (ALL THE TIME, MOST OF THE TIME, A LITTLE MORE THAN HALF OF THE TIME, A LITTLE LESS THAN HALF OF THE TIME A BIT OF THE TIME, AT NO POINT IN TIME)	
28. EMOTIONAL FUNCTIONING/WELLBEING	FEELING CALM AND RELAXED (ALL THE TIME, MOST OF THE TIME, A LITTLE MORE THAN HALF OF THE TIME, A LITTLE LESS THAN HALF OF THE TIME A BIT OF THE TIME, AT NO POINT IN TIME)	
28. EMOTIONAL FUNCTIONING/WELLBEING	FEELING OPTIMISTIC ABOUT THE FUTURE	
28. EMOTIONAL FUNCTIONING/WELLBEING	FEELING WELL RESTED (ALL THE TIME, MOST OF THE TIME, A LITTLE MORE THAN HALF OF THE TIME, A LITTLE LESS THAN HALF OF THE TIME A BIT OF THE TIME, AT NO POINT IN TIME)	
28. EMOTIONAL FUNCTIONING/WELLBEING	FULL OF ENERGY (ALL THE TIME, MOST OF THE TIME, A LITTLE MORE THAN HALF OF THE TIME, A LITTLE LESS THAN HALF OF THE TIME A BIT OF THE TIME, AT NO POINT IN TIME)	
28. EMOTIONAL FUNCTIONING/WELLBEING	HAPPINESS/GOOD MOOD (ALL THE TIME, MOST OF THE TIME, A LITTLE MORE THAN HALF OF THE TIME, A LITTLE LESS THAN HALF OF THE TIME A BIT OF THE TIME, AT NO POINT IN TIME)	

28. EMOTIONAL FUNCTIONING/WELLBEING	WELLBEING	8
29. COGNITIVE FUNCTIONING	AFFECTED MEMORY	
29. COGNITIVE FUNCTIONING	ATTENTION OR MEMORY DEFICIT	
29. COGNITIVE FUNCTIONING	BRAIN FOG	
29. COGNITIVE FUNCTIONING	COGNITIVE DISTURBANCES	
29. COGNITIVE FUNCTIONING	COGNITIVE DYSFUNCTION	
29. COGNITIVE FUNCTIONING	COGNITIVE FUNCTION IMPAIRMENT	
29. COGNITIVE FUNCTIONING	COGNITIVE IMPAIRMENT/'BRAIN FOG'	
29. COGNITIVE FUNCTIONING	COGNITIVE SCORE	
29. COGNITIVE FUNCTIONING	COMMUNICATION SCORE	
29. COGNITIVE FUNCTIONING	CONCENTRATION DIFFICULTIES	
29. COGNITIVE FUNCTIONING	CONCENTRATION IMPAIRMENT/CONCENTRATION DEFICIT	
29. COGNITIVE FUNCTIONING	CONCENTRATION PROBLEMS	
29. COGNITIVE FUNCTIONING	CONFUSION	
29. COGNITIVE FUNCTIONING	CONFUSION, DISORIENTATION, OR DROWSINESS	
29. COGNITIVE FUNCTIONING	CONFUSION/LACK OF CONCENTRATION	
29. COGNITIVE FUNCTIONING	DIFFICULT TO FIND THE RIGHT WORD	
29. COGNITIVE FUNCTIONING	DIFFICULTIES CONCENTRATING	
29. COGNITIVE FUNCTIONING	DIFFICULTIES MANAGING SCHOOL	
29. COGNITIVE FUNCTIONING	DIFFICULTY CONCENTRATING	
29. COGNITIVE FUNCTIONING	DISORIENTATION	
29. COGNITIVE FUNCTIONING	FORGETFULNESS	
29. COGNITIVE FUNCTIONING	IMPAIRED ATTENTION	
29. COGNITIVE FUNCTIONING	LEARNING DIFFICULTIES	
29. COGNITIVE FUNCTIONING	MEMORY IMPAIRMENT	
29. COGNITIVE FUNCTIONING	MEMORY LOSS	

29. COGNITIVE FUNCTIONING	MEMORY PROBLEMS	
29. COGNITIVE FUNCTIONING	PROBLEMS SPEAKING OR COMMUNICATING	
29. COGNITIVE FUNCTIONING	PROBLEMS WITH CONCENTRATION	
29. COGNITIVE FUNCTIONING	PROBLEMS WITH MEMORY	
29. COGNITIVE FUNCTIONING	REDUCED CONCENTRATION	
29. COGNITIVE FUNCTIONING	SHORT-TERM MEMORY LOSS	
29. COGNITIVE FUNCTIONING	SOCIAL-EMOTIONAL SCORE	
29. COGNITIVE FUNCTIONING	SPEECH AND LANGUAGE DISORDERS	
29. COGNITIVE FUNCTIONING	SPEECH DISTURBANCES	
29. COGNITIVE FUNCTIONING	SPEECH/LANGUAGE ABNORMALITIES	
29. COGNITIVE FUNCTIONING	STATES OF CONFUSION	
29. COGNITIVE FUNCTIONING	THINKING CLEARLY	
29. COGNITIVE FUNCTIONING	TROUBLE CONCENTRATING	
29. COGNITIVE FUNCTIONING	TROUBLE FORMING WORDS	
29. COGNITIVE FUNCTIONING	TROUBLE REMEMBERING THINGS	
29. COGNITIVE FUNCTIONING	YOUR MIND GOING BLANK	41
30. GLOBAL QUALITY OF LIFE	EARLY EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON HRQoL	
30. GLOBAL QUALITY OF LIFE	EMOTIONAL FUNCTIONING	
30. GLOBAL QUALITY OF LIFE	HEALTH RELATED QUALITY OF LIFE	
30. GLOBAL QUALITY OF LIFE	HEALTH-RELATED QUALITY OF LIFE (HRQoL) OF PATIENTS DIAGNOSED WITH COVID-19	
30. GLOBAL QUALITY OF LIFE	HEALTH-RELATED QUALITY OF LIFE AND SOCIAL IMPACT	
30. GLOBAL QUALITY OF LIFE	LATE EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME ON HRQoL	
30. GLOBAL QUALITY OF LIFE	PHYSICAL FUNCTIONING	
30. GLOBAL QUALITY OF LIFE	QoL AT TIME OF SURVEY	
30. GLOBAL QUALITY OF LIFE	QoL BEFORE COVID-19	
30. GLOBAL QUALITY OF LIFE	QUALITY OF LIFE	

30. GLOBAL QUALITY OF LIFE	QUALITY OF LIFE AND SOCIAL IMPACT	
30. GLOBAL QUALITY OF LIFE	QUALITY OF LIFE/FUNCTIONING	
30. GLOBAL QUALITY OF LIFE	SCHOOL FUNCTIONING	
30. GLOBAL QUALITY OF LIFE	SOCIAL FUNCTIONING	14
31. PERCEIVED HEALTH STATUS	HEALTH AFTER COVID-19	
31. PERCEIVED HEALTH STATUS	HEALTH BEFORE COVID-19	
31. PERCEIVED HEALTH STATUS	HEALTH STATUS BEFORE AND AFTER COVID-19	
31. PERCEIVED HEALTH STATUS	SELF-RATED HEALTH	4
32. DELIVERY OF CARE		
33. PERSONAL CIRCUMSTANCES	DISABILITY	
33. PERSONAL CIRCUMSTANCES	LIFE EVENTS	
33. PERSONAL CIRCUMSTANCES	LIFE EVENTS EXPLAINING THE MENTIONED CHANGES	
33. PERSONAL CIRCUMSTANCES	SPENDING TIME OUTSIDE	
33. PERSONAL CIRCUMSTANCES	SPENDING TIME WATCHING TV, PLAYING VIDEO/COMPUTER GAMES, OR USING SOCIAL MEDIA FOR EDUCATIONAL PURPOSES, INCLUDING SCHOOL/NURSERY WORK	
33. PERSONAL CIRCUMSTANCES	SPENDING TIME WATCHING TV, PLAYING VIDEO/COMPUTER GAMES, OR USING SOCIAL MEDIA FOR NON-EDUCATIONAL PURPOSES	6
34. ECONOMIC	INDEX OF MULTIPLE DEPRIVATION	1
35. HOSPITAL		
36. NEED FOR FURTHER INTERVENTION	ADMISSION TO THE ICU	
36. NEED FOR FURTHER INTERVENTION	CHANGE IN CHILD SARS-CoV-2 TREATMENT RECORD	
36. NEED FOR FURTHER INTERVENTION	CONTACTS TO THE GENERAL PRACTITIONER	
36. NEED FOR FURTHER INTERVENTION	DIAGNOSES	
36. NEED FOR FURTHER INTERVENTION	DURATION OF PICU HOSPITALIZATION	
36. NEED FOR FURTHER INTERVENTION	DURATION OF WARD ADMISSION	
36. NEED FOR FURTHER INTERVENTION	FREQUENCY OF FAMILY DOCTOR VISITS AFTER RECOVERING FROM COVID-19	
36. NEED FOR FURTHER INTERVENTION	FREQUENCY OF SPECIALIST VISITS AFTER RECOVERING FROM COVID-19	

36. NEED FOR FURTHER INTERVENTION	HOSPITAL ADMISSION AFTER THE COVID-19 (HOW MANY TIMES, REASON, NAME OF HOSPITAL)	
36. NEED FOR FURTHER INTERVENTION	HOSPITAL READMISSION	
36. NEED FOR FURTHER INTERVENTION	HOSPITALIZATION AFTER SARS-CoV-2 INFECTION	
36. NEED FOR FURTHER INTERVENTION	HOSPITALIZATION/REHOSPITALIZATION	
36. NEED FOR FURTHER INTERVENTION	HOSPITALIZATIONS	
36. NEED FOR FURTHER INTERVENTION	INCREASE IN PRIMARY HEALTH CARE USE	
36. NEED FOR FURTHER INTERVENTION	MEDICAL RESOURCE UTILIZATION FOR PATIENTS DIAGNOSED WITH COVID-19	
36. NEED FOR FURTHER INTERVENTION	NEED FOR HOSPITAL CARE	
36. NEED FOR FURTHER INTERVENTION	NUMBER OF GP VISITS	
36. NEED FOR FURTHER INTERVENTION	PEDIATRIC INTENSIVE CARE UNIT HOSPITALIZATION	
36. NEED FOR FURTHER INTERVENTION	PRESCRIBED DRUGS	
36. NEED FOR FURTHER INTERVENTION	REQUIRED A REFERRAL TO A PEDIATRIC CARDIOLOGIST FOR UNSPECIFIED REASONS	
36. NEED FOR FURTHER INTERVENTION	REQUIRED PHYSICAL THERAPY	
36. NEED FOR FURTHER INTERVENTION	STUDIES PERFORMED AFTER RECOVERING FROM COVID-19	
36. NEED FOR FURTHER INTERVENTION	VISIT TO OTHER HEALTH FACILITY AFTER THE COVID-19 (HOW MANY TIMES, REASON)	23
37. SOCIETAL/CARER BURDEN	CAREGIVER SARS-CoV-2 VACCINATION STATUS	
37. SOCIETAL/CARER BURDEN	CAREGIVER SYMPTOMS	
37. SOCIETAL/CARER BURDEN	CHANGE IN CAREGIVER SARS-CoV-2 TREATMENT RECORD	
37. SOCIETAL/CARER BURDEN	HELP REQUEST BECAUSE OF COVID-19 CONSEQUENCES	4
38. ADVERSE EVENTS/EFFECTS	EPISODE OF POST-TUSSIVE VOMITING	
38. ADVERSE EVENTS/EFFECTS	ADVERSE EVENTS	2

\*DODD S, CLARKE M, BECKER L, MAVERGAMES C, FISH R, WILLIAMSON PR. A TAXONOMY HAS BEEN DEVELOPED FOR OUTCOMES IN MEDICAL RESEARCH TO HELP IMPROVE KNOWLEDGE DISCOVERY. J CLIN EPIDEMIOL. 2018;96:84-92. DOI:10.1016/J.JCLINEPI.2017.12.020

#### 4. THE LIST OF OUTCOMES PRESENTED TO THE DELPHI PARTICIPANTS.

Domain name	Outcome	Lay definition
Mortality/survival	Survival	How long does someone live
Physiological/clinical	Cardiovascular functioning, symptoms, and conditions	New onset or worsening of problems affecting the heart (e.g. irregular heartbeat, palpitations, pounding or racing heartbeat, resting heartbeat changes, pericarditis/myocarditis (heart inflammation)); problems with the blood vessels (i.e., veins or arteries), changes in blood pressure
Physiological/clinical	Endocrine and metabolic functioning, symptoms, and conditions	New onset or worsening of problems related to the glands (type of body organ) that make hormones, hormonal balance (e.g. diabetes, thyroid problems, adrenal gland or steroid problems, changes in body weight, bone mineral problems), menstrual cycle, early onset of puberty
Physiological/clinical	Hearing-related functioning, symptoms, and conditions	New onset or worsening of problems with hearing (e.g., hearing loss, ringing or buzzing in the ears, increased sensitivity to sounds)
Physiological/clinical	Gastrointestinal functioning, symptoms, and conditions	New onset or worsening of problems with swallowing, stomach aches, nausea (feeling the need to vomit), vomiting, heartburn/reflux (stomach acid coming back up into the mouth and causing an unpleasant, sour taste), diarrhoea, constipation, gas, indigestion, lack of pleasure while eating (some children describe this as “food and eating is yuck”)
Physiological/clinical	Pain	New onset or worsening discomfort in the body that can include sharp or burning pain, dull ache, or stinging or throbbing, including pain that comes and goes, or is persistent, or chronic (ongoing) pain; increased sensitivity to pain (feeling pain even upon minor stimuli which have not caused pain before), inability to control pain with usual painkillers
Physiological/clinical	Fatigue or Exhaustion	New onset or worsening of feeling exhausted, having too little energy, or needing more rest, including fatigue not relieved by rest
Physiological/clinical	Sleep-related functioning, symptoms, and conditions	New onset or worsening of problems with falling or staying asleep, need for sleep medications/aids, excessive sleeping, or lack of refreshing sleep/poor sleep quality, increased nightmares and/or sleepwalking



Physiological/clinical	Muscle and joint symptoms and conditions	New onset or worsening of joint or muscle problems, such as muscle weakness or joint stiffness or swelling/inflammation
Physiological/clinical	Taste- and/or smell-related functioning, symptoms, and conditions	New onset or worsening problems with altered or reduced/loss of taste or smell (e.g., familiar things smell or taste bad or different, tasting or smelling things that are not there)
Physiological/clinical	Neuro-cognitive system functioning, symptoms, and conditions	New onset or worsening of dizziness/lightheadedness, tics (involuntary movements caused by spasm-like contractions of muscles, most commonly involving the face, mouth, eyes, head, neck or shoulders; vocal tics are sounds uttered unintentionally), fainting, headache, migraine, abnormal movements, tremors/shaking, seizures/fits, muscle twitching, tingling feelings, decreased sensation, inability to move part of the body, lack of coordination, speech difficulty; Problems with memory, communication, concentration, having "brain fog", understanding instructions, including interpretation of words; Abnormal child development (e.g. learning new skills, such as crawling/walking and talking, developmental regression)
Physiological/clinical	Mental / Psychological functioning, symptoms, and conditions	New onset or worsening problems with emotions and mood, including anxiety/worrying, panic attacks, separation anxiety, fear, aggression, irritability, anger, excessive crying, easily getting upset, feeling of guilt, depression, suicidal thoughts, or post-traumatic stress symptoms (having flashbacks to a stressful event), obsessions (intrusive unwanted thoughts) and compulsions (repetative actions or behaviours linked to obsessions)
Physiological/clinical	Kidney and urinary-related functioning, symptoms, and conditions	New onset or worsening problems with kidney function or need for dialysis or problems with urination (i.e., wee/pee) including infections, burning or stinging, higher frequency or urgency (i.e. feeling of needing), incontinence (inability to control urination/"wetting yourself")
Physiological/clinical	Respiratory functioning, symptoms, and conditions	New onset or worsening problems with lungs or breathing (e.g., shortness of breath/shortness of air/not getting enough air, chest tightness or coughing/wheezing, problems with breathing through the nose including blocked and runny nose), sinusitis (infection of the sinuses (air-filled spaces in the bones of your face around the nose))
Physiological/clinical	Skin, hair, dental and/or nail-related functioning, symptoms, and conditions	New onset or worsening problems with ulcers, skin rash and/or peeling, itch, red spots or lumps on toes (COVID toes), hair thinning/loss, changes in nails and teeth

Physiological/clinical	Post-exertion symptoms	New onset or worsening of different symptoms following physical or mental activities or emotions that could previously be tolerated (e.g. thinking, moving, socialising), which that can last for a prolonged duration (multiple days/weeks)
Physiological/clinical	Vision-related functioning, symptoms, and conditions	New onset or worsening of problems with vision (e.g., problems seeing or blurred vision, increased sensitivity to light, colour misperception, loss of vision), dry eyes or feeling of a grit/sand in eyes
Physiological/clinical	Fever/body temperature changes	New onset or worsening of problems related to the body temperature without a known cause (e.g. fever that comes and goes, prolonged low-grade fever, chills or shivers, feeling too cold or too hot)
Life impact	Satisfaction with life, or personal enjoyment	New onset or worsening of problems with satisfaction with life or personal enjoyment, loss of being the person who you were before COVID-19, feeling “left out”/“missing out”, feeling that “the world is moving, while you are stuck”
Life impact	Physical functioning, symptoms, and conditions	New onset or worsening problems with daily physical abilities (activities), including arm/leg shaking or unsteadiness, mobility, walking, dressing, playing or eating, growth
Life impact	Social role-functioning and relationships problems	New onset or worsening problems with connecting with others, including family members and friends, maintaining and creating new friendships and personal/romantic relationship, social activities
Life impact	Work/occupational and study changes	New onset or worsening problems with being able to resume usual level of work, study, attendance, less engagement/ participation in extracurricular activities
Life impact	Stigma	New onset or worsening problems with fear or experiences of being discriminated against, bullied, excluded from activities, ignored, including by employer/school/nursery/university, medical professionals, social groups, family/friends/neighbours, or others
Resource use	Healthcare resource utilisation	Seeing more healthcare professionals (e.g., doctor, physiotherapist, psychologist), taking new medications, returning to the hospital or emergency care, including complementary/alternative medicine (e.g., acupuncturists, naturopaths), medical devices/technology
Resource use	Family/carer burden	Increasing/developing a burden on caregiver/family or friends/classmates/colleagues/teachers; impact of sickness on other people in your life, including relationships between the carers

## 5. FULL DETAILS OF DELPHI PARTICIPANTS.

	Round 1 <i>n</i> = 214	Round 2 <i>n</i> =154
<b>Stakeholder group, <i>n</i></b>		
Children and young people ( $\leq 18$ years old) who have experience of living with Long COVID	26	21
Family and carers of children and young people ( $\leq 18$ years old) with Long COVID	115	76
Health professionals who have experience treating children and young people ( $\leq 18$ years old) with Long COVID	37	32
Researchers studying Long COVID in children and young people ( $\leq 18$ years old)	36	25
Other	<i>participants reclassified after R1 review and analysed within appropriate groups</i>	
<b>Gender, <i>n</i></b>		
Male	47	34
Female	166	119
Non-binary	1	1
Other	0	0

Prefer not to answer	0	0
<b>Age group, n</b>		
2-5	1	1
6-11	5	2
12-18	21	19
18-29	5	2
30-39	35	31
40-49	94	67
50-59	45	27
60-69	7	4
70-79	1	1
>=80	0	0
<b>Countries, n</b>		

Argentina	2	2
Australia	7	5
Belarus	1	1
Belgium	1	1
Canada	5	1
Chile	2	2
Croatia	2	1
Cyprus	1	1
Czech Republic	1	1
Egypt	1	1
France	5	4
Germany	2	1
Greece	2	2

Indonesia	1	0
Ireland	3	2
Israel	1	1
Italy	6	5
Japan	1	0
Jordan	1	1
Lithuania	1	1
Malaysia	1	1
Netherlands	10	10
New Zealand	4	3
Norway	2	1
Panama	1	0
Peru	2	2

Poland	1	1
Republic of Korea	1	1
Romania	3	3
Russia	9	4
Spain	3	1
Sweden	1	0
Switzerland	1	0
Syria	1	1
Ukraine	1	0
United Kingdom	108	81
United States of America	19	12
<b>Ethnicity, <i>n</i></b>		
White	180	130

South Asian	5	4
Hispanic/Latino/Spanish	8	6
East Asian/Pacific Islander	5	2
Indigenous peoples	0	0
Black	1	1
Middle Eastern/North African	6	5
Other	Mixed Asian = 1 Turkish = 1 Mixed - English/Pakistani = 1 British Indian = 1 Indian and West Indian =1 Jewish = 1 Mix: White British and South Asian = 1 This is a continuum. I identify with several =1	Turkish = 1 British Indian = 1 Indian and West Indian =1 Mixed - English/Pakistani = 1 Jewish = 1 Mix: White British and South Asian = 1



## 6. ATTRITION BETWEEN ROUNDS ONE AND TWO.

<b>Stakeholder</b>	<b>Number registered n (% of total registrations)</b>	<b>Completed** R1 n (% of registered)</b>	<b>Number of participants invited to R2 n (% of completed R1)</b>	<b>Completed** R2 n (% of completed R1 and invited to R2)</b>
<i>CHILDREN AND YOUNG PEOPLE (≤18 YEARS OLD) WHO HAVE EXPERIENCE OF LIVING WITH POST COVID CONDITION (ALSO KNOWN AS LONG COVID)</i>	30 (12.9)	26 (11.4)	26 (100)	21 (9.8)
<i>FAMILY AND CARERS OF CHILDREN AND YOUNG PEOPLE (≤18 YEARS OLD) WITH LONG COVID</i>	124 (53.5)	115 (50.4)	115 (100)	76 (35.5)
<i>HEALTH PROFESSIONALS WHO HAVE EXPERIENCE TREATING CHILDREN AND YOUNG PEOPLE (≤18 YEARS OLD) WITH LONG COVID</i>	37 (15.9)	37 (16.2)	37 (100)	32 (15)
<i>RESEARCHERS STUDYING LONG COVID IN CHILDREN AND YOUNG PEOPLE (≤18 YEARS OLD)</i>	37 (15.9)	36 (15.8)	36 (100)	25 (11.7)

<b>TOTAL</b>	228 (98.3)	214 (93.9)	214 (100)	154 (72)
<p>*232 total registrations with 1 deleted as duplicate and 3 withdrawn during R1</p> <p>**Completed = completed/rated &gt;50% of outcomes</p>				

## 7. RESULTS FOLLOWING TWO ROUNDS OF DELPHI AND SELECTION OF OUTCOMES FOR THE CONSENSUS MEETING

Domain	Outcome	Stakeholder groups voting results																					
		Overall result	Children and young people (≤18 years old) with Long COVID and their family and carers						Result	Health professionals working with children and young people (≤18 years old) with Long COVID						Result	Researchers studying Long COVID in children and young people (≤18 years old)						Result
			Round 1(n=141)			Round 2(n=97)				Round 1(n=37)			Round 2(n=32)				Round 1(n=36)			Round 2(n=25)			
			%	%	%	%	%	%		%	%	%	%	%	%		%	%	%	%	%	%	
1-3	4-6	7-9	1-3	4-6	7-9	1-3	4-6	7-9	1-3	4-6	7-9	1-3	4-6	7-9	1-3	4-6	7-9						
Mortality/survival	Survival	Discuss	3.2	23.8	73	3.2	21.3	75.5	Medium	19.4	22.2	58.3	15.6	25	59.4	Medium	5.7	11.4	82.9	4	8	88	In
Physiological/clinical	Cardiovascular functioning; symptoms; and conditions	In	5.3	9.8	85	2.1	9.6	88.3	In	10.8	18.9	70.3	9.4	6.3	84.4	In	8.3	13.9	77.8	4	8	88	In
	Endocrine and metabolic functioning; symptoms;	Out	6.2	17.2	76.6	3.2	20.4	76.3	Medium	10.8	48.6	40.5	6.3	56.3	37.5	Out	13.9	47.2	38.9	16	56	28	Out

	and conditions																						
	Hearing-related functioning; symptoms; and conditions	<b>Out</b>	23·3	38·8	38	22·2	51·1	26·7	<b>Out</b>	29·7	43·2	27	34·4	53·1	12·5	<b>Out</b>	25·7	45·7	28·6	28	56	16	<b>Out</b>
	Gastrointestinal functioning; symptoms; and conditions	<b>Discuss</b>	2·2	21·3	76·5	0	15·8	84·2	<b>In</b>	8·1	27	64·9	6·3	12·5	81·3	<b>In</b>	11·1	50	38·9	16	40	44	<b>Out</b>
	Pain	<b>Discuss</b>	1·4	15·9	82·6	1	10·3	88·7	<b>In</b>	5·4	27	67·6	3·1	9·4	87·5	<b>In</b>	11·1	27·8	61·1	4	28	68	<b>Medium</b>
	Fatigue or Exhaustion	<b>In</b>	0·7	3·6	95·7	0	2·1	97·9	<b>In</b>	2·7	10·8	86·5	0	6·3	93·8	<b>In</b>	0	19·4	80·6	0	8	92	<b>In</b>
	Sleep-related functioning; symptoms; and conditions	<b>Discuss</b>	0·7	17·4	81·9	0	13·5	86·5	<b>In</b>	2·7	24·3	73	0	15·6	84·4	<b>In</b>	2·8	38·9	58·3	4	24	72	<b>Medium</b>
	Muscle and joint symptoms and conditions	<b>Discuss</b>	3·6	23·7	72·7	0	19·8	80·2	<b>In</b>	5·4	37·8	56·8	3·1	25	71·9	<b>Medium</b>	5·6	38·9	55·6	8	36	56	<b>Medium</b>
	Taste-and/or smell-related functioning; symptoms; and	<b>Out</b>	27·1	33·8	39·1	28	47·3	24·7	<b>Out</b>	16·2	35·1	48·6	21·9	40·6	37·5	<b>Out</b>	0	50	50	0	60	40	<b>Out</b>

conditions																						
Neuro-cognitive system functioning; symptoms; and conditions	In	1·5	10·9	87·6	0	5·3	94·7	In	5·4	5·4	89·2	3·1	3·1	93·8	In	2·8	13·9	83·3	0	4	96	In
Mental / Psychological functioning; symptoms; and conditions	Discuss	6·5	19·4	74·1	4·2	16·8	78·9	Medium	2·7	13·5	83·8	0	3·1	96·9	In	2·8	22·2	75	0	8	92	In
Kidney and urinary-related functioning; symptoms; and conditions	Out	19·7	28·3	52	22·6	36·6	40·9	Out	29·7	45·9	24·3	25	53·1	21·9	Out	25·7	42·9	31·4	29·2	54·2	16·7	Out
Respiratory functioning; symptoms; and conditions	Discuss	3·8	27·5	68·7	4·3	24·7	71	Medium	5·4	27	67·6	0	18·8	81·3	In	0	11·1	88·9	0	12	88	In
Skin; hair; dental and/or nail-related functioning; symptoms; and conditions	Out	18·3	45	36·6	23·4	53·2	23·4	Out	24·3	48·6	27	25	65·6	9·4	Out	22·2	61·1	16·7	32	60	8	Out

	Post-exertion symptoms	<b>Discuss</b>	0·7	5·8	93·5	0	1	99	In	10·8	13·5	75·7	0	12·5	87·5	In	8·3	36·1	55·6	8	24	68	Medium
	Vision-related functioning; symptoms; and conditions	<b>Out</b>	10·7	35·1	54·2	12·9	38·7	48·4	Out	27	51·4	21·6	28·1	59·4	12·5	Out	27·8	44·4	27·8	28	60	12	Out
	Fever/body temperature changes	<b>Out</b>	8·2	35·8	56	9·5	36·8	53·7	Medium	21·6	54·1	24·3	12·5	75	12·5	Out	22·2	55·6	22·2	16	76	8	Out
Life impact	Satisfaction with life; or personal enjoyment	<b>Discuss</b>	3	14·1	83	0	10·3	89·7	In	5·4	27	67·6	0	25	75	Medium	0	37·1	62·9	0	26·9	73·1	Medium
	Physical functioning; symptoms; and conditions	<b>In</b>	0·7	3·7	95·6	0	2·1	97·9	In	0	10·8	89·2	0	9·4	90·6	In	2·9	8·6	88·6	0	8	92	In
	Social role-functioning and relationships problems	<b>Discuss</b>	5·3	28·6	66·2	1	32	67	Medium	2·8	22·2	75	0	12·9	87·1	In	0	31·4	68·6	4	32	64	Medium
	Work/occupational and study changes	<b>Discuss</b>	2·3	14·3	83·5	0	12·2	87·8	In	2·8	16·7	80·6	0	12·9	87·1	In	2·9	25·7	71·4	0	24	76	Medium
	Stigma	<b>Out</b>	9·2	41·2	49·6	7·2	41·2	51·5	Medium	5·7	57·1	37·1	6·5	61·3	32·3	Out	17·1	48·6	34·3	16	68	16	Out

									m														
Resource use	Healthcare resource utilisation	Query discuss at end	2.9	18.4	78.7	2	20.4	77.6	Medium	0	36.1	63.9	0	37.5	62.5	Medium	8.6	17.1	74.3	7.7	19.2	73.1	Medium
	Family/carer burden	Query discuss at end	1.5	29.6	68.9	0	21.9	78.1	Medium	2.8	22.2	75	0	28.1	71.9	Medium	0	31.4	68.6	0	24	76	Medium

<b>Total</b>		
<b>In</b>		<b>4</b>
<b>Out</b>		<b>8</b>
<b>Discuss</b>		<b>11</b>
<b>Query discuss at end</b>		<b>2</b>

## 8. DELPHI PROCESS AND CONSENSUS MEETING RESULTS

Domain	Outcome	Outcome description	% Children and young people/Family and carers of children and young people (≤18 years old) with Long COVID voting 7-9 in R2 of online Delphi	% HCPs voting 7-9 in R2 of online Delphi	Researchers voting 7-9 in R2 of online Delphi	% Children and young people/Family and carers of children and young people (≤18 years old) with Long COVID voting 7-9 in consensus meeting	% HCPs/ Researchers voting 7-9 in consensus meeting	Result
Physiologic al/clinical outcomes	<b>Fatigue or Exhaustion</b>	New onset or worsening of feeling exhausted, having too little energy, or needing more rest, including fatigue not relieved by rest	97·9	93·8	92	N/A	N/A	Included in the COS following Delphi survey
	<b>Neuro-cognitive system functioning, symptoms, and conditions</b>	New onset or worsening of dizziness/lightheadedness, tics (involuntary movements caused by spasm-like contractions of muscles, most commonly involving the face, mouth, eyes, head,	94·7	93·8	96	N/A	N/A	Included in the COS following Delphi survey

		neck or shoulders; vocal tics are sounds uttered unintentionally), fainting, headache, migraine, abnormal movements, tremors/shaking, seizures/fits, muscle twitching, tingling feelings, decreased sensation, inability to move part of the body, lack of coordination, speech difficulty; Problems with memory, communication, concentration, having "brain fog", understanding instructions, including interpretation of words; Abnormal child development (e.g. learning new skills, such as crawling/walking and talking, developmental regression)						
	<b>Cardiovascular functioning,</b>	New onset or worsening of	88·3	84·4	88	N/A	N/A	Included in the COS



	<b>symptoms, and conditions</b>	problems affecting the heart (e.g. irregular heartbeat, palpitations, pounding or racing heartbeat, resting heartbeat changes, pericarditis/myocarditis (heart inflammation)); problems with the blood vessels (i.e., veins or arteries), changes in blood pressure						following Delphi survey
<b>Life impact outcomes</b>	<b>Physical functioning, symptoms, and conditions</b>	New onset or worsening problems with daily physical abilities (activities), including arm/leg shaking or unsteadiness, mobility, walking, dressing, playing or eating, growth	97.9	90.6	92	N/A	N/A	Included in the COS following Delphi survey
<b>Physiologic/clinical outcomes</b>	<b>Post-exertion symptoms</b>	New onset or worsening of different symptoms following physical or mental activities or emotions that could previously be tolerated (e.g. thinking, moving, socialising), which	99	87.5	68	100	84	Included in the COS following discussion at the consensus meeting

		that can last for a prolonged duration (multiple days/weeks)						
	<b>Gastrointestinal functioning; symptoms; and conditions</b>	New onset or worsening of problems with swallowing, stomach aches, nausea (feeling the need to vomit), vomiting, heartburn/reflux (stomach acid coming back up into the mouth and causing an unpleasant, sour taste), diarrhoea, constipation, gas, indigestion, lack of pleasure while eating (some children describe this as “food and eating is yuck”)	84·2	81·3	44	100	84	Included in the COS following discussion at the consensus meeting
<b>Life impact outcomes</b>	<b>Work/occupational and study changes</b>	New onset or worsening problems with being able to resume usual level of work, study, attendance, less engagement/participation in	87·8	87·1	76	100	91	Included in the COS following discussion at the consensus meeting

		extracurricular activities						
<b>Physiologic al/clinical outcomes</b>	<b>Endocrine and metabolic functioning, symptoms, and conditions</b>	New onset or worsening of problems related to the glands (type of body organ) that make hormones, hormonal balance (e.g. diabetes, thyroid problems, adrenal gland or steroid problems, changes in body weight, bone mineral problems), menstrual cycle, early onset of puberty	76.3	37.5	28	N/A	N/A	Excluded following Delphi survey
	<b>Hearing-related functioning, symptoms, and conditions</b>	New onset or worsening of problems with hearing (e.g., hearing loss, ringing or buzzing in the ears, increased sensitivity to sounds)	26.7	12.5	16	N/A	N/A	Excluded following Delphi survey
	<b>Taste- and/or smell-related functioning, symptoms, and conditions</b>	New onset or worsening problems with altered or reduced/loss of taste or smell (e.g., familiar things	24.7	37.5	40	N/A	N/A	Excluded following Delphi survey

		smell or taste bad or different, tasting or smelling things that are not there)						
	<b>Kidney and urinary-related functioning, symptoms, and conditions</b>	New onset or worsening problems with kidney function or need for dialysis or problems with urination (i.e., wee/pee) including infections, burning or stinging, higher frequency or urgency (i.e. feeling of needing), incontinence (inability to control urination/“wetting yourself”)	40·9	21·9	16·7	N/A	N/A	Excluded following Delphi survey
	<b>Skin, hair, dental and/or nail-related functioning, symptoms, and conditions</b>	New onset or worsening problems with ulcers, skin rash and/or peeling, itch, red spots or lumps on toes (COVID toes), hair thinning/loss, changes in nails and teeth	23·4	9·4	8	N/A	N/A	Excluded following Delphi survey
	<b>Vision-related functioning,</b>	New onset or worsening of problems with vision (e.g.,	48·4	12·5	12	N/A	N/A	Excluded following

	<b>symptoms, and conditions*</b>	problems seeing or blurred vision, increased sensitivity to light, colour misperception, loss of vision), dry eyes or feeling of a grit/sand in eyes						Delphi survey
	<b>Fever/body temperature changes</b>	New onset or worsening of problems related to the body temperature without a known cause (e.g. fever that comes and goes, prolonged low-grade fever, chills or shivers, feeling too cold or too hot)	53·7	12·5	8	N/A	N/A	Excluded following Delphi survey
<b>Life impact outcomes</b>	<b>Stigma</b>	New onset or worsening problems with fear or experiences of being discriminated against, bullied, excluded from activities, ignored, including by employer/school/nursery/university, medical professionals, social groups,	51·5	32·3	16	N/A	N/A	Excluded following Delphi survey

		family/friends/neighbours, or others						
<b>Mortality outcomes</b>	<b>Survival</b>	How long does someone live	75.5	59.4	88	27	8	Excluded following discussion at the consensus meeting
<b>Physiologic al/clinical outcomes</b>	<b>Sleep-related functioning; symptoms; and conditions</b>	New onset or worsening of problems with falling or staying asleep, need for sleep medications/aids, excessive sleeping, or lack of refreshing sleep/poor sleep quality, increased nightmares and/or sleepwalking	86.5	84.4	72	91	75	Excluded following discussion at the consensus meeting
	<b>Muscle and joint symptoms and conditions</b>	New onset or worsening of joint or muscle problems, such as	80.2	71.9	56	72	34	Excluded following discussion at the

		muscle weakness or joint stiffness or swelling/inflammation						consensus meeting
	<b>Mental Psychological functioning</b> /	New onset or worsening problems with emotions and mood, including anxiety/worrying, panic attacks, separation anxiety, fear, aggression, irritability, anger, excessive crying, easily getting upset, feeling of guilt, depression, suicidal thoughts, or post-traumatic stress symptoms (having flashbacks to a stressful event), obsessions (intrusive unwanted thoughts) and compulsions (repetative actions or behaviours linked to obsessions)	78.9	96.9	92	10	59	Excluded following discussion at the consensus meeting
	<b>Respiratory functioning</b>	New onset or worsening problems with lungs or breathing (e.g., shortness of	71	81.3	88	45	66	Excluded following discussion at the

		breath/shortness of air/not getting enough air, chest tightness or coughing/wheezing, problems with breathing through the nose including blocked and runny nose), sinusitis (infection of the sinuses (air-filled spaces in the bones of your face around the nose))						consensus meeting
	<b>Pain</b>	New onset or worsening discomfort in the body that can include sharp or burning pain, dull ache, or stinging or throbbing, including pain that comes and goes, or is persistent, or chronic (ongoing) pain; increased sensitivity to pain (feeling pain even upon minor stimuli which have not caused pain before), inability to control pain with usual painkillers	88.7	87.5	68	80	75	Excluded following discussion at the consensus meeting



<b>Life impact outcomes</b>	<b>Satisfaction with life; or personal enjoyment</b>	New onset or worsening of problems with satisfaction with life or personal enjoyment, loss of being the person who you were before COVID-19, feeling “left out”/“missing out”, feeling that “the world is moving, while you are stuck”	89·7	75	73·1	63	34	Excluded following discussion at the consensus meeting
	<b>Social role-functioning and relationships problems</b>	New onset or worsening problems with connecting with others, including family members and friends, maintaining and creating new friendships and personal/romantic relationship, social activities	67	87·1	64	27	18	Excluded following discussion at the consensus meeting
<b>Resource Use Outcomes</b>	<b>Family/carer burden</b>	Increasing/developing a burden on caregiver/family or friends/classmates /colleagues/teachers; impact of sickness on other people in your life, including	78·1	71·9	76	100	34	Excluded following discussion at the consensus meeting

		relationships between the carers						
	<b>Healthcare resource utilisation</b>	Seeing more healthcare professionals (e.g., doctor, physiotherapist, psychologist), taking new medications, returning to the hospital or emergency care, including complementary/alternative medicine (e.g., acupuncturists, naturopaths), medical devices/technology	77.6	62.5	73.1	44	8	Excluded following discussions at the consensus meeting

## 9. PC-COS CHILDREN PROJECT STEERING COMMITTEE GROUP AUTHORS

ASIAH KASSIM<sup>1</sup>, JENNIFER R. CHEVINSKY<sup>2</sup>, KAREN CHOONG<sup>3</sup>, RAE DUNCAN<sup>4</sup>, SUSANNA ESPOSITO<sup>5</sup>, REBECCA FOSTER<sup>6</sup>, ALLA GUEKHT<sup>7</sup>, ALLISON JAURE<sup>8</sup>, CARRIE MACKENZIE<sup>9</sup>, VIVIENNE MATTHIES-BONN<sup>10</sup>, KAREN MATVIENKO-SIKAR<sup>11</sup>, LORRAINE MCCLOUD<sup>12</sup>, DONNA C MCPARLAND<sup>12</sup>, VICTOR DANIEL MIRON<sup>13</sup>, SRINIVAS MURTHY<sup>14</sup>, SARAH O CONNELL<sup>12</sup>, MARGARET O'HARA<sup>15</sup>, ANNA OGWONOWSKA-SLODOWNIK<sup>16</sup>, JANA PAVARE<sup>17</sup>, PAULA ROBERTSON<sup>18</sup>, JEREMY ROSSMAN<sup>19</sup>, OANA SĂNDULESCU<sup>20</sup>, SHARON H. SAYDAH<sup>21</sup>, JOCHEN SCHMITT<sup>22</sup>, MALCOLM "CALUM" G. SEMPLE<sup>23,24</sup>, ROZ SHAFRAN<sup>25</sup>, AUSRA SNIPAITIENE<sup>26</sup>, ARNE SØRAAS<sup>27</sup>, TERENCE STEPHENSON<sup>28</sup>, LOLA TULEN<sup>29</sup>, GONZALO VALENZUELA GALAZ<sup>30</sup>, DAVID VICKERS<sup>31</sup>, DANIEL CHRISTIAN VILSER<sup>32</sup>, MICHAELA WAAK<sup>33</sup>, JULIE WELLS<sup>12</sup>, ELIZABETH WHITTAKER<sup>34,35</sup>, MICHELLE WINER<sup>12</sup>, ALAN ASMANOV<sup>36</sup>, PASQUALE COMBERIATI<sup>37</sup>

<sup>1</sup> Hospital Tunku Azizah, (Women and Children Hospital), Kuala Lumpur, Malaysia

<sup>2</sup> CDC COVID-19 Emergency Response, USA

- 3 McMaster University, Hamilton, Canada
- 4 Newcastle's Freeman Hospital, Newcastle upon Tyne, UK
- 5 University of Parma, Parma, Italy
- 6 Royal Surrey Hospital, Guildford , UK
- 7 Moscow Research and Clinical Centre for Neuropsychiatry, Moscow, Russia
- 8 The University of Sydney, Sydney, Australia
- 9 Sheffield Children's NHS Foundation Trust, Sheffield, UK
- 10 Long Covid kinderen, the Netherlands
- 11 University College Cork, Cork, Ireland
- 12 Long Covid Kids
- 13 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 14 University of British Columbia, Vancouver, Canada
- 15 Long Covid Support, London, UK
- 16 Faculty of Rehabilitation, Jozef Pilsudski University of Physical Education in Warsaw, Warsaw, Poland
- 17 Riga Stradins University, Riga, Latvia
- 18 Paediatric Emergency Department at Eric Williams Medical Complex, Trinidad and Tobago
- 19 University of Kent, Canterbury, UK
- 20 Department of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania and National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, Romania
- 21 CDC/DDID/NCIRD/CORVD; CDC COVID-19 Response, USA
- 22 Center for Evidence-based Healthcare, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
- 23 University of Liverpool, Liverpool, UK

- 24 Alder Hey Children's Hospital, Liverpool, UK
- 25 UCL Great Ormond Street Institute of Child Health, London, UK
- 26 Lithuanian University of Health Sciences Pediatric Department, Kaunas, Lithuania
- 27 Oslo University Hospital, Oslo, Norway
- 28 University College London, London, UK
- 29 National Institute for Public Health and the Environment, Bilthoven, the Netherlands
- 30 Department of Paediatric Infectious Diseases and Immunology, Pontifical Catholic University of Chile, Santiago, Chile.
- 31 Cambridgeshire Community Services NHS Trust, Cambridgeshire, UK
- 32 Hospital for Pediatrics and Adolescent Medicine, Jena University Hospital, Jena, Germany
- 33 The University of Queensland, Brisbane, Australia
- 34 Section of Paediatric Infectious Diseases, Imperial College London, London, UK
- 35 Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK
- 36 The Research and Clinical Institute for Pediatrics named after Academician Yuri Veltishev of the Pirogov Russian National Research Medical University, Moscow, Russia
- 37 Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Italy

#### 10. PC-COS CHILDREN PROJECT STEERING COMMITTEE (TABLE)

Name, Middle name	Surname	Institution	Country	Expertise
EUROPEAN REGION				
Daniel	Munblit	Division of Care in Long Term Conditions, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London/Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health,	UK/Russia	Allergy, Paediatrics, COS development

		Sechenov First Moscow State Medical University (Sechenov University)/Research and Clinical Center for Neuropsychiatry		
Anastasia	Chernyavskaya	Department of Paediatrics and Paediatric Rheumatology, Sechenov First Moscow State Medical University (Sechenov University)/National Medical Research Center for Children's Health	Russia	Paediatrics
Nina	Seylanova	Independent researcher	UK	Critical Care, COS development
Olalekan	Aiyegbusi	University of Birmingham	UK	Outcomes Methodology
Anbarasu	Anbu	Alder Hey Children's NHS Foundation Trust	UK	Lead for CYP Long Covid and ME/CFS service at Alder Hey Children's NHS Foundation Trust Hub
Christian	Apfelbacher	University of Magdeburg	Germany	Epidemiology, COS development
Liat	Ashkenazi-Hoffnung	Schneider Children's Medical Center of Israel	Israel	Pediatric Infectious Diseases
Caroline	Brackel	Amsterdam University Medical Centers/Department of Pediatrics, Tergooi Hospital	The Netherlands	Paediatric Pulmonology
Danilo	Buonsenso	Università Cattolica del Sacro Cuore/Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS	Italy	Paediatrics, Infectious Diseases
Pasquale	Comberiati	Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa	Italy	Paediatrics, Allergy
Daniele	Dona'	Department for Women's and Children's Health, University of Padua	Italy	Pediatric Infectious Diseases Consultant, co-leader of the Clinical Working Group of the VERDI project (101045989), which is funded by the European Union

Audrey	DunnGalvin	University of Cork	Ireland	Psychology
Jon	Genuneit	Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University	Germany	Immunology
Helen	Goss	Long Covid Kids	UK	Family member of a person with living experience of Long COVID
Sarah E.	Hughes	Institute of Applied Health Research, University of Birmingham	UK	Outcomes Methodology
Christina	Jones	University of Surrey	UK	Adherence, Allergy, Asthma, Behaviour change, Diabetes, Evidence synthesis, Health services research, Long term conditions, Physical and psychological health comorbidities, Psychological interventions, Research methods
Sammie	McFarland	Long Covid Kids	UK	Family member of a person with living experience of Long COVID
Timothy R	Nicholson	King's College London	UK	Neuropsychiatry
Terry	Segal	University College London Hospitals NHS Foundation Trust	UK	Adolescence, paediatric endocrinology (growth and puberty), chronic fatigue syndrome, obesity, anorexia nervosa (medical aspects), chronic medically unexplained symptoms
Louise	Sigfrid	University of Oxford	UK	Public Health, Infectious diseases
Claire	Thorne	Population, Policy and Practice Dept, University College London GOS Institute of Child Health	UK	Infectious diseases epidemiology
Susanne	Vijverberg	Amsterdam University Medical Centers	The Netherlands	Paediatric asthma
John O.	Warner	Imperial College London	UK	Allergy, Respiratory, Pediatrics

Paula R	Williamson	University of Liverpool	UK	Methodology, COS development
Sarah O	Connell	Long Covid Kids	UK	Family member of a person with living experience of Long COVID
Rae	Duncan	Newcastle's Freeman Hospital	UK	Cardiology, LCK (PPI)
Susanna	Esposito	University of Parma	Italy	Paediatrics, Infectious Diseases
Rebecca	Foster	Sherwood Forest Hospitals Foundation Trust	UK	Paediatrics
Alla	Guekht	Moscow Research and Clinical Centre for Neuropsychiatry	Russia	Neurology
Carrie	Mackenzie	Sheffield Children's NHS Foundation Trust	UK	Paediatrics
Vivienne	Matthies-Bonn	Long Covid kinderen	the Netherlands	Family member of a person with living experience of Long COVID
Karen	Matvienko-Sikar	University of Cork	Ireland	COS development
Lorraine	McCloud	Long Covid Kids	UK	Family member of a person with living experience of Long COVID
Donna C	McParland	Long Covid Kids	UK	Family member of a person with living experience of Long COVID
Victor Daniel	Miron	Carol Davila University of Medicine and Pharmacy	Romania	Paediatrics, Infectious Diseases
Margaret	O'Hara	Long Covid Support	UK	Patient and Public Involvement in Research
Anna	Ogonowska-Slodownik	Faculty of Rehabilitation, Jozef Pilsudski University of Physical Education in Warsaw	Poland	Physiotherapy and physical education
Jana	Pavare	Riga Stradins University	Latvia	Paediatrics, Infectious Diseases
Jeremy	Rossmann	University of Kent	UK	Virology, Public Health

Oana	Sandulescu	Department of Infectious Diseases, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy	Romania	Infectious Diseases
Jochen	Schmitt	University of Dresden	Germany	Methodology, COS development
Malcolm "Calum" G.	Semple	University of Liverpool/Alder Hey Children's Hospital	UK	Infectious Diseases
Roz	Shafran	UCL GOS Institute of Child Health	UK	Population, Policy & Practice Dept
Ausra	Snipaitiene	Lithuanian University of Health Sciences Pediatric Department	Lithuania	Paediatrics, Rheumatology
Arne	Søraas	Oslo University Hospital	Norway	Bacteriology
Terence	Stephenson	University College London	UK	Paediatrics
Lola	Tulen	National Institute for Public Health and the Environment	the Netherlands	Epidemiology
Kees	van den Wijngaard	National Institute for Public Health and the Environment	the Netherlands	Epidemiology
David	Vickers	Cambridgeshire Community Services NHS Trust	UK	Paediatrics
Daniel Christian	Vilser	Hospital for Pediatrics and Adolescent Medicine, Jena University Hospital	Germany	Pediatric Cardiology, Pediatric Emergency Medicine
Julie	Wells	Long Covid Kids	UK	Family member of a person with living experience of Long COVID
Elizabeth	Whittaker	Imperial College London	UK	Paediatrics, Infectious Diseases
Alan	Asmanov	The Research and Clinical Institute for Pediatrics named after Academician Yuri Veltischev of the Pirogov Russian National Research Medical University	Russia	Pediatrics, ENT
REGION OF THE AMERICAS				



Dale M.	Needham	Outcomes After Critical Illness and Surgery (OACIS) Research Group, Johns Hopkins University/Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine/Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine	USA	Critical Care, Physical Medicine and Rehabilitation
Nikita	Nekliudov	Institute for Health Metrics and Evaluation, University of Washington	USA	Health Services Research
Carlos	Oliveira	Yale University School of Medicine, Department of Pediatrics, Section of Infectious Diseases/Yale University School of Public Health, Department of Biostatistics, Division of Health Informatics/Yale New Haven Children's Hospital	USA	Paediatric infectious diseases
Laura	Malone	Kennedy Krieger Institute/Johns Hopkins University	USA	Paediatric long COVID
Jennifer R.	Chevinsky	CDC COVID-19 Emergency Response	USA	Epidemiology, Population Health, Preventive Medicine
Karen	Choong	McMaster University	Canada	Paediatrics
Sharon H.	Saydah	CDC/DDID/NCIRD/DVD; CDC COVID-19 Response	USA	Epidemiology
Michelle	Winer	Long Covid Kids	USA	Family member of a person with living experience of Long COVID
Srinivas	Murthy	University of British Columbia	Canada	Critical Care, Paediatrics, Infectious Diseases
Paula	Robertson	Paediatric Emergency Department at Eric Williams Medical Complex	Trinidad and Tobago	Paediatrics
Gonzalo	Valenzuela Galaz	Pontifical Catholic University of Chile	Chile	Paediatrics, Infectious Diseases
WESTERN PACIFIC REGION				
Asiah	Kassim	Kuala Lumpur Women and Children Hospital	Malaysia	Paediatrics

Allison	Jaure	The University of Sydney	Australia	Chronic Disease, COS development
Michaela	Waak	The University of Queensland	Australia	Paediatrics, Neurology, Paediatric intensive care/Retrieval medicine
EASTERN MEDITERRANEAN REGION				
Ali Akbar	Asadi-Pooya	Epilepsy Research Center, Shiraz University of Medical Sciences/Jefferson comprehensive epilepsy center, Thomas Jefferson University	Iran/USA	Neurological/cognitive problems in long COVID
WHO				
Wouter	de Groote	WHO - Rehabilitation Team	Switzerland	Global Health, Rehabilitation Medicine
Krutika	Kuppalli	WHO	Switzerland	Infectious Diseases, Global Health
Nicoline	Schiess	WHO - Brain Health Team	Switzerland	Global health, Neurology
Wilson Milton	Were	WHO	Switzerland	Infectious Diseases, Global Health, Epidemiology
Janet Victoria	Diaz	WHO	Switzerland	Critical Care, Pulmonary Medicine, Global Health